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ABSTRACT 
 Sestrins are highly conserved, stress-inducible proteins that protect against cellular damage 
and the progression of age-associated and diabetic pathologies. These include fat accumulation, 
insulin resistance, muscle degeneration, cardiac dysfunction, mitochondrial pathologies, and 
tumorigenesis. Sestrin has two established anti-aging functions: reducing oxidative stress and 
regulating the mechanistic target of rapamycin (mTOR) signaling network. This thesis focuses on 
the regulation of mTOR signaling. 
 First, I defined a new pathway in the Sestrin2 signaling network. Sestrin2 strongly activates 
AKT, a major metabolic regulator downstream of the insulin signaling cascade. I found that the 
mechanism for Sestrin2-induced AKT activation occurred through two large protein complexes: 
GAP Activity TOwards Rags 2 (GATOR2), a pentameric protein complex that binds to Sestrin2, 
and mTOR Complex 2 (mTORC2), a kinase upstream of AKT. GATOR2 bridged Sestrin2 and 
mTORC2 and was functionally required for Sestrin2-induced AKT activation. In addition, Sestrin2 
bound to AKT’s pleckstrin homology (PH) domain and induced AKT translocation to the plasma 
membrane. Although Sestrin2 and GATOR2 were known to inhibit mTORC1, this work defined 
a new mechanism for Sestrin2 and GATOR2 in activating mTORC2. 
 Next, I characterized other components in the Sestrin2 signaling network by generating 
transgenic mice with liver-specific knockouts. mTORC1 has two signaling arms required for full 
activation: nutrient sensing and growth factors. Nutrients input to the GATOR1 complex, which 
consists of Nprl2, Nprl3, and DEPDC5, while growth factors input to the TSC complex. First, I 
generated a DEPDC5 knockout mouse to constitutively activate the nutrient sensing arm of 
 xii 
mTORC1. I found that liver-specific DEPDC5 deletion (Depdc5Δhep) showed enlarged zone 3 
hepatocytes, increased sensitivity to acetaminophen toxicity, and decreased lipid accumulation in 
the liver. Next, I generated Depdc5Δhep/Tsc1Δhep double knockout (DKO) mice to concurrently 
activate both the growth factor and nutrient sensing arms of mTORC1 in the liver. The DKO mice 
showed severe phenotypes by two months with significantly lower body weights and more liver 
injury. Interestingly, the severe pathological phenotypes were all reversed after only 10 days of 
intraperitoneal injections of either rapamycin, an mTORC1 inhibitor, or Tempol, an oxidative 
stress reducer. Surprisingly, tauroursodeoxycholic acid (TUDCA), an ER stress reliever, was lethal 
to the DKO mice, suggesting a potential feedback mechanism for ER stress in the context of 
hyperactive mTORC1. In addition, transcriptomic analysis of WT, Depdc5Δhep, Tsc1Δhep, and DKO 
livers showed that DKO livers had distinct transcriptomic profiles with selective upregulation of 
oxidative stress genes. Taken together with the Tempol experiment, this suggests that hyperactive 
hepatic mTORC1 induces liver injury through oxidative stress signaling. Finally, systemic 
characterization without any interventions showed that 2-month-old DKO mice had insulin 
resistance, and 5-month-old DKO mice exhibited spontaneous hepatocellular carcinoma (HCC). 
Overall, this work developed and characterized a new mouse model of hyperactive mTOR that 
could potentially be utilized for future studies as a 2-month nonalcoholic steatohepatitis (NASH) 
model or 5-month HCC model. 
 In summary, the work from this thesis has furthered our understanding of Sestrin2 signaling. 
First, we defined a novel mechanism where Sestrin2 and GATOR2 activate the mTORC2 pathway. 
Secondly, we developed and characterized a genetic mouse model with a hyperactive mTORC1 
liver that spontaneously develops NASH by two months and HCC by five months. This work 
 xiii 
provides a mechanistic understanding of how Sestrin is able to protect against diabetic pathological 




Sestrin, a versatile anti-aging molecule 
One theory for the cause of aging is the accumulation of cellular damage, facilitated by 
environmental stressors that induce genotoxic or oxidative stress (1). Although appropriate levels 
of reactive oxygen species (ROS) are necessary for physiological homeostasis (2), excessive ROS 
accumulation can cause damage to DNA and proteins, thereby facilitating the aging process (1,2). 
Nutritional overabundance and obesity are also well-established promoters of aging, while 
appropriate dietary restriction extends longevity and healthspan in virtually all model organisms 
(1). One of the major signaling components that can mediate the nutritional effect on aging is 
mechanistic target of rapamycin complex 1 (mTORC1). Genetic or pharmacological inhibition of 
mTORC1 extends longevity and healthspan in most organisms including mammals (3-5), 
suggesting a central role of mTORC1 in the acceleration of aging. 
Sestrins are a family of highly conserved proteins that are induced upon various conditions 
of stress, including DNA damage and oxidative stress. Invertebrates have a single orthologue, 
while vertebrates have three paralogues, Sestrin1-3 (Table 1.1) (6). In cultured cells, Sestrin1 and 
Sestrin2 reduced ROS (7) and suppressed mTORC1 activity (8), suggesting that this family of 
proteins may perform anti-aging functions through the inhibition of these two well-characterized 
aging facilitators. Indeed, genetic depletion of Sestrin in many animal models, including  
 
1 This chapter represents a published manuscript: Ho A, Cho CS, Namkoong S, Cho US, Lee JH. Biochemical Basis 
of Sestrin Physiological Activities. Trends in Biochemical Sciences (2016) 
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Figure 1.1 Structure of hSesn2 with highlighted functional domains. Ribbon diagram of full-
length hSesn2 (PDB ID: 5CUF (10)). Sesn-A, Sesn-B and Sesn-C domains, which were originally 
predicted through a phylogenetic analysis (19), are represented in blue, pink and green, 
respectively. The oxidoreductase active site of Sesn-A is magnified in the top left, and the catalytic 
cysteine (C125) and conserved residues of the proton relay system (Y127 and H132) are indicated. 
These residues were found to be critical for the antioxidant function of hSesn2. The GATOR2-
interacting surface of the Sesn-C domain is magnified on the bottom left with the critical residues 
(D406 and D407; the ‘DD motif’) labeled. This DD motif is required for the interaction between 
hSesn2 and GATOR2, and for subsequent control of AMPK and mTORC1 signaling. Finally, the 
leucine-binding site of the Sesn-C domain is magnified on the right. The top representation is the 
crystallized structure without added leucine (PDB ID: 5CUF (10)), and the bottom representation 
is the structure with leucine (PDB ID: 5DJ4 (20)). No significant conformational change was 
observed between these two structures. Illustrations of the protein structure were generated with 
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worms (21), flies (22) and mice (11,16,17,23-25), has led to the accelerated progression of diverse 
age- and obesity-associated pathological disorders including fat accumulation, insulin resistance, 
muscle degeneration, cardiac dysfunction, mitochondrial pathologies and tumorigenesis, which 
could be relieved by treatments that suppressed ROS or mTORC1 signaling. However, the 
biochemical mechanisms underlying how this small, 55kDa protein performs such versatile 
physiological functions and prevents the progression of diverse age-associated pathologies have 
remained elusive. Recently, our understanding of Sestrin protein biochemistry has dramatically 
improved. Major recent findings include identifying GAP activity towards Rags 2 (GATOR2), a 
heteropentameric protein complex that consists of WDR59, WDR24, Mios, Seh1L, and Sec13, as 
a direct physical target of Sestrin (13-15), acquiring an in-depth understanding of the antioxidant 
activity of Sestrin (10,11,26), identifying Sestrin as an amino acid sensor (18,20,27,28), and 
determining the three-dimensional molecular structure of Sestrin (10,20). The Sestrin structure 
revealed three functional sites for each of its identified activities: mTOR regulation, ROS 
suppression and leucine binding (Figure 1.1) (10,20). In this review, we discuss the current 
findings related to Sestrin function and signaling while highlighting questions elicited by these 
discoveries. 
 
Sestrin suppresses oxidative damage 
Sestrins are transcriptionally induced upon oxidative damage through diverse transcription 
factors including p53, Nrf2, AP-1 and FoxOs (6,29). Cells overexpressing Sestrin are protected 
from oxidative damage (7,9,29), while Sestrin deficiency renders cells and tissues hypersensitive 
to oxidative stress (7,11,22,30). Therefore, Sestrin is considered an important component of 
 4 
antioxidant defense, and many different theories have been proposed to explain its antioxidant 
activity. 
 
Sestrin as a Prx reductase 
Sestrin exhibits a remote sequence similarity to AhpD, an antioxidant protein in 
Mycobacterium tuberculosis (7). AhpD has two known redox functions: detoxification of 
alkylhydroperoxides (a group of hydrophobic ROS (31)), and reduction of the cysteine disulfides 
(Cys-S-S-Cys) of AhpC (32), a peroxiredoxin (Prx)-family peroxidase in M. tuberculosis. 
Mutation of Cys125 in Sestrin (SestrinCS), which corresponds to one of the two catalytic 
cysteines in AhpD, abolished the ability of Sestrin to protect cells from oxidative stress (7). Based 
on this functional similarity, it was originally proposed that Sestrin acts as a reductase for Prx. 
However, unlike AhpD, which can reduce the cysteine disulfides of AhpC (32), Sestrin2 was 
suggested to function as a reductase for cysteine sulfinic acids (Cys-SO2H), an overoxidized form 
of Prx (7). Supporting this argument, induction of Sestrin expression significantly reduced the 
level of overoxidized Prx in two independent studies (7,33). 
Although the role of Sestrin as a Prx reductase can explain its antioxidant function, another 
study rebuked this hypothesis; purified Sestrin did not exhibit any intrinsic cysteine sulfinic acid 
reductase activity toward Prx, while sulfiredoxin (Srx) did (34). A genetic study in Caenorhabditis 
elegans further demonstrated that Sestrin is not genetically required for recycling overoxidized 
Prx (35). Therefore, it is now widely agreed that Sestrin is not a stand-alone sulfinic acid reductase 
for Prx (6,26). Nevertheless, it seems clear that the induction of Sestrin can promote recycling of 
overoxidized Prx (7,33) and reduce oxidative damage in cells (7,9,29). These effects likely occur 
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through an indirect transcriptional upregulation of Srx or direct detoxification of ROS, 
mechanisms that will be discussed in more detail below. 
 
Sestrin as an autophagy regulator 
Autophagic degradation of dysfunctional mitochondria, known as mitophagy, is critical for 
redox homeostasis because the accumulation of damaged mitochondria results in excessive ROS 
production that can lead to diverse degenerative pathologies (36). Sestrin can upregulate autophagy 
through AMP-activated Protein Kinase (AMPK) activation and mTORC1 inhibition. 
Correspondingly, Sestrin was found to induce autophagy during diverse environmental stresses 
that provoke mitochondrial dysfunction (11,37-40).  
A genetic study in Drosophila also supported the importance of autophagy in mediating 
the antioxidant activity of Sestrin because the loss of Sestrin led to autophagy impairment, 
resulting in accumulation of damaged mitochondria and subsequent elevation of ROS in skeletal 
muscle (22). Similar muscle phenotypes were also observed in Sestrin-deficient C. elegans (21). 
These phenotypes were dependent on AMPK/mTORC1 misregulation and autophagy abrogation 
because (i) pharmacological AMPK activation or mTORC1 inhibition restored mitochondrial 
homeostasis in Sestrin-deficient flies, (ii) SestrinCS, a redox-inactive Sestrin that can still regulate 
AMPK/mTORC1 signaling (8), also restored mitochondrial homeostasis, and (iii) RNAi-mediated 
downregulation of Ampk or Atg1, the fly homolog of ULK1, resulted in mitochondrial phenotypes 
like those seen in Sestrin-deficient flies (22). 
Even though the mitophagy-regulating function of Sestrin is important for redox 
homeostasis, Sestrin also contributes to redox biology through additional mechanisms. First, in 
several non-muscle cell types, SestrinCS was less effective than SestrinWT in suppressing ROS 
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accumulation (7,41). Second, Sestrin suppressed ROS in physiological contexts that do not involve 
mitochondrial damage, including neuronal synaptic stimulation (42), replicative senescence (30), 
macrophage peroxide signaling (33), brown adipocyte thermogenesis (41) and renal dopamine 
signaling (43). Thus, Sestrin-mediated redox regulation is not narrowly confined to the control of 
mitophagy and autophagy but must involve additional mechanisms. 
 
Sestrin as an Nrf2 regulator 
Nrf2 is a transcription factor that upregulates the expression of a wide range of antioxidant 
genes including Prx, Srx, glutathione-S-transferase (GST) and thioredoxin (Trx) (44). In normal 
environments, kelch-like ECH-associated protein 1 (Keap1) binds to Nrf2 and targets it for 
proteasomal degradation (Figure 1.2A). Keap1 inactivation occurs through oxidation of its several 
cysteine residues (44) or by autophagic elimination mediated by an autophagy adapter 
p62/sequestosome-1 (SQSTM1) (45,46).  
Sestrin2 was found to associate with both Keap1 and SQSTM1 (11), as well as autophagy-
initiator ULK1 (47). Sestrin2 promotes ULK1-induced phosphorylation of SQSTM1 (47), which 
facilitates Keap1 degradation and Nrf2 activation (48). This pathway can explain how Sestrin2 
functions as an antioxidant through upregulation of Nrf2 and its antioxidant targets (Figure 1.2B) 
(26). Indeed, the Sestrin2-Keap1-Nrf2 pathway was shown to be physiologically important for the 
antioxidant defense of hepatocytes against nutritional (11) and chemical (49) stress. 
Another intriguing point is that both Sestrin2 and SQSTM1, which contribute to the degradation 
of Keap1, are direct transcriptional targets of Nrf2 (50,51). Therefore, Nrf2-dependent induction 
of Sestrin2 and SQSTM1 can generate a positive feedback loop that guarantees the maximal 




Figure 1.2. Sestrin-mediated regulation of Nrf2. (A) Under normal environmental conditions, 
Nrf2 is inactivated when Keap1 binds and targets it for proteasomal degradation through the Cul3-
based E3 ligase (Cul3) and associated RING box protein (Rbx), which recruits an E2 ligase to tag 
Nrf2 with ubiquitin (ub). (B) Under conditions of oxidative stress, Sestrin2 (Sesn2) and SQSTM1 
are expressed. Sesn2 binds ULK1, an initiator of autophagy, and SQSTM1, an autophagy adaptor 
protein. This interaction between the three proteins promotes ULK1-dependent phosphorylation 
of SQSTM1, which then specifically targets Keap1 for autophagic elimination. Now, Nrf2 is freed 
from Keap1, translocates to the nucleus, and promotes transcriptional activation of genes 
controlled by the antioxidant response element (ARE), including Sesn2, SQSTM1 and antioxidant 
enzymes such as Prx, Srx, and GST. 
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  Although this Nrf2-dependent mechanism provides a convincing explanation of the 
antioxidant role of Sestrin2, several questions still remain: (i) is the physical interaction between  
Sestrin2, Keap1, SQSTM1 and ULK1 supported by structural studies, (ii) can Sestrin2, in 
conjunction with Keap1, regulate Nrf2 activity in a redox-sensitive manner, and (iii) does 
Sestrin regulation of AMPK and mTORC1 signaling also contribute to the autophagic regulation 
of Keap1 and Nrf2. Assessing the effect of specific mutations that block the peroxidase activity of  
Sestrin or mTORC1-regulating function (Table 1.2) may provide some clues about its regulation 
of the Keap1-Nrf2 pathway. 
 
Sestrin as a peroxidase 
Recent determination of the human Sestrin2 (hSesn2) structure by X-ray crystallography 
allowed us to gain novel insights into its antioxidant function. The crystal structure revealed that 
hSesn2 contains two structurally similar subdomains, Sesn-A and Sesn-C. Both subdomains share 
significant structural homology with the Ralstonia eutropha protein YP_296737.1, which belongs 
to a family of alkylhydroperoxidases, including the M. tuberculosis AhpD (10,20). Moreover, the 
Sesn-A domain of hSesn2 contains the helix–turn–helix oxidoreductase motif (Figure 1.1) that has 
an intact proton relay system with the catalytic cysteine (Cys125) and other key residues (Tyr127 
and His132) conserved in AhpD and YP_296737.1 (10). 
Subsequent biochemical studies demonstrated that hSesn2 is indeed an active 
alkylhydroperoxidase (10). This conclusion was based on the observations that (i) recombinant 
hSesn2 catalyzed the reduction of cumene hydroperoxide, an alkylhydroperoxide, at an efficiency 
comparable to M. tuberculosis AhpC and AhpD; (ii) substitutions of the key catalytic residues of 
Sesn-A, including Cys125, Tyr127 and His132 (Figure 1.1), abolished the alkylhydroperoxidase 
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Mutations in Sesn-A domain 
H86A - - - - O - X (20) 
C125S X X O O O - - (7,8,10,11) 
Y127F - X - O - - - (10) 
H132A - X - O - - - (10) 
S190W - - - X X - O (18) 
Mutations in Sesn-B domain 
L261A - - - O O - X (18) 
Mutations in Sesn-C domain 
T374A - - - - - - X (20) 
Y375F - - - - O - X (20) 
T386A - - - - O - X (20) 




- - - X X - - (10) 
D406A - O - X X X - (10) 
D407A - O - X X X - (10) 
D406A/ 
D407A - - - - X - O (20) 




- - - OX - - - (10,27) 
W444E - - - - O - X (20) 
W444L - - - - O - ▲ (20) 
E451A - - - O O - X (18) 
E451Q - - - - O - X (20) 
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activity of hSesn2; and (iii) the proposed reaction intermediate form—cysteine sulfenic acid (Cys-
SOH)—of hSesn2 was detectable in wild-type hSesn2 but not Cys125-substituted hSesn2 
(hSesn2CS). 
Although the structural and biochemical evidence demonstrates that hSesn2 has intrinsic 
peroxidase activity, the physiological ROS substrate of hSesn2 still needs to be identified. 
Hydrogen peroxide, which is among the most abundant and biologically significant ROS in cells, 
is not efficiently reduced by hSesn2 (10). The only known substrate for hSesn2 is cumene 
hydroperoxide (10), which is not a physiological ROS in any known cell type. Because hSesn2 is 
expected to be specific for hydrophobic alkylhydroperoxides (10), lipid hydroperoxides may be a 
physiologically relevant substrate for Sestrin as they are implicated in diverse age- and obesity-
associated diseases (52-54). It is also possible that hSesn2 acts as a redox sensor, if the reversible 
oxidation of Cys125 in hSesn2 is found to affect its function in promoting autophagy or regulating 
Nrf2. 
 
Sestrin regulates the mTOR signaling network 
Independent of redox regulation, Sestrin is also involved in stress-dependent mTOR 
regulation. mTOR is present in two different protein kinase complexes, mTORC1 and mTORC2. 
Sestrin specifically inhibits mTORC1 by inhibiting Rheb and RagA/B, the two GTPases 
essential for mTORC1 activation. The AMPK-TSC2 pathway mediates the effects of Sestrin on 
Rheb, while the GATOR1-GATOR2 complexes are responsible for the effects of Sestrin on 
RagA/B (Figure 1.3). GATOR1 is a heterotrimeric protein complex that consists of DEPDC5, 
Nprl2, and Nprl3 with GAP activity towards RagA/B. Interestingly, although Sestrin strongly 
inhibits mTORC1, it activates mTORC2 through several independent mechanisms.  
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Sestrin as an AMPK regulator 
The study that first described Sestrin-mediated mTORC1 control concluded that this 
regulation was dependent on AMPK (8). In this study, Sestrin was shown to associate with the 
TSC1:TSC2 complex and promote the activation of TSC2 by AMPK-mediated phosphorylation. 
Sestrin also increased AMPK phosphorylation at Thr172 (8), a marker of AMPK activation. As 
TSC2 is a GTPase-activating protein (GAP) for Rheb, Sestrin-dependent TSC2 activation 
inactivates Rheb and mTORC1 (Figure 1.3B). Supporting this model, pharmacological (via 
compound C) or shRNA-mediated inhibition of AMPK and TSC2 blunted the inhibition of 
mTORC1 by Sestrin (8). Importantly, Sestrin was necessary for DNA damage-induced inhibition 
of mTORC1 (8), which was also dependent on the activation of AMPK and TSC2 (55). 
The AMPK-activating role of Sestrin was widely observed and shown to be important 
for mTORC1 control in diverse cellular contexts (23,24,40,56-58). Genetic studies in Drosophila 
also supported this model because the AMPK-TSC2 axis was critical for the effect of Sestrin in 
controlling tissue growth and attenuating age-associated pathologies (22,59). Metabolic 
phenotypes of Sestrin2-deficient mice, including insulin resistance and steatohepatitis, were also 
strongly suppressed by pharmacological (via AICAR) or viral (via Ad-AMPKCA) activation of 
AMPK (17,23), further supporting the idea that AMPK is the critical downstream target of 
Sestrin controlling metabolic homeostasis. 
Although this evidence indicates that AMPK is physiologically important for mediating 
Sestrin activity, Sestrin was recently found to inhibit mTORC1 in AMPK-null mouse embryonic 
fibroblasts (MEF) (14,15,27), suggesting that AMPK is not the only target of Sestrin in the 
mTORC1 pathway. In addition, the molecular mechanism of Sestrin-induced AMPK activation 




Figure 1.3. Sestrin-mediated regulation of mTORC1. (A) Under unstressed conditions, Sestrin 
expression and activity is low, and GATOR1 and GATOR2 form a supercomplex. mTORC1 is 
fully activated; activated RagA/B:RagC/D localizes mTORC1 to the lysosomal membrane, and 
GTP-loaded Rheb activates mTORC1’s kinase activity. (B) Under conditions of stress, Sestrin is 
upregulated and binds GATOR2. This then frees GATOR1 from GATOR2 inhibition, and 
GATOR1 subsequently acts as a GAP for RagA/B. Inactivated RagA/B:RagC/D is then unable to 
localize mTORC1 to the lysosome, and mTORC1 disperses to the cytosol. In addition, the Sestrin-
GATOR2 interaction also promotes AMPK activation through unclear biochemical mechanisms 
possibly involving LKB1, the major kinase upstream of AMPK. Activated AMPK then 
phosphorylates TSC2, a GAP for Rheb, leaving Rheb now in its inactive GDP-loaded form. AMPK 
also phosphorylates Raptor, a regulatory subunit of mTORC1, and this phosphorylation inhibits 
the kinase activity of mTORC1 (60). Sestrin may also regulate RagA/B proteins as a GDI. Solid 




AMPK and LKB1 (24,61) and that Sestrin induces the expression of AMPK regulatory subunits 
to achieve maximal AMPK activation (61). Although these models do explain a mechanism for 
Sestrin-induced AMPK activation, more robust experimental evidence is needed to clarify the 
exact biochemical role of Sestrin in AMPK signaling. 
 
Sestrin as a Rag GDI 
 In search of alternative mechanisms to account for Sestrin regulation of mTORC1 in an 
AMPK-independent manner, Sestrin was suggested to act as a GDP dissociation inhibitor (GDI) 
to inhibit RagA/B (27). This model was based on the following observations: (i) Sestrin could 
not inhibit mTORC1 when constitutively active RagB was expressed, (ii) Sestrin exhibited 
physical interaction with the RagA/B:RagC/D complex, (iii) Sestrin inhibited GTP loading on 
the RagA/B proteins in an in vitro assay, and (iv) Sestrin shows limited sequence homology to 
human and mouse GDI1 proteins (27). 
 Although this model could explain the observations that Sestrin-mediated mTORC1 
inhibition is dependent on RagA/B (13-15,27), several findings contradict this model. Crystal 
structures of hSesn2 show no structural homology between Sestrin and GDI proteins (10,20) and 
actually indicate that the proposed GDI motif in Sestrin has a very different conformation from 
GDI1. Indeed, mutations of the putative GDI motif did not prevent Sestrin from inhibiting 
mTORC1 (10). In addition, although the initial study reported that hSesn2 immunostaining 
overlaps with the Rag complex on the lysosomal membrane (27), subsequent studies with higher 
immunofluorescence resolution demonstrated that hSesn2 is actually excluded from the 
lysosomal surface (14,15), indicating that hSesn2 does not directly control RagA/B activity on 
the lysosomal membrane. Finally, the direct physical interaction between Sestrin and RagA/B 
 14 
was undetectable in several subsequent experiments (15). These observations suggest that 
Sestrin-mediated control of RagA/B could occur through indirect mechanisms involving 
additional signaling components. 
 
Sestrin as a GATOR modulator 
 In several independent labs, proteomic studies identified a strong physical interaction 
between Sestrin and GATOR2 (13-15), a RagA/B-regulating hetero-pentameric protein complex 
(62). GATOR2 is known to suppress GATOR1, a heterotrimeric complex that functions as a 
GAP for RagA/B (63). Therefore, Sestrin was postulated to bind GATOR2, liberating GATOR1 
from GATOR2-mediated inhibition, and thereby promote the RagA/B-inhibiting activity of 
GATOR1 (Figure 1.3) (13-15). Supporting this model, silencing or knocking out GATOR1 
components abolished inhibition of mTORC1 by Sestrin (13-15). The genetic relationship 
between Sestrin, GATOR1 and GATOR2 was also conserved in Drosophila; silencing GATOR1 
inhibited suppression of wing growth by Sestrin, and mutations of GATOR2 restored autophagy 
defects in Sestrin-null flies (15). These results suggest that Sestrin inhibits RagA/B-dependent 
mTORC1 activation through modulation of the GATOR complexes. 
 Even though these results implicate a functional relationship between Sestrin, GATOR2, 
GATOR1 and RagA/B, the biochemical mechanisms of how Sestrin modulates the GATOR 
complexes are still elusive with noticeable inconsistencies between the reports. Two papers 
indicated that Sestrin does not affect the association between GATOR1 and GATOR2 (13,14), 
while another study demonstrated that high levels of Sestrin expression destabilized the 
GATOR1:GATOR2 supercomplex (15). One paper indicated that Sestrin does not affect the GTP 
loading status of RagB (14), while the other two papers showed that GTP loading of RagB was 
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altered by Sestrin overexpression (15,27). This confusion is in part because the molecular natures 
of the GATOR1 and GATOR2 complexes are not yet biochemically defined. For example, the 
biochemical mechanism of how GATOR2 suppresses GATOR1 is also unknown. 
 Despite these unanswered questions, the recently determined crystal structure of hSesn2 
led to the discovery of a structural motif that mediates the hSesn2-GATOR2 interaction. As 
previously mentioned, hSesn2 has two-fold pseudosymmetrical subdomains, Sesn-A and Sesn-
C (Figure 1.1), each of which is structurally homologous to an alkylhydroperoxidase (10,20). 
Whereas the helix–turn–helix oxidoreductase motif was found to be well-conserved and 
functional in Sesn-A, the corresponding structural motif was absent in Sesn-C and replaced with 
a long loop structure containing two surface-exposed aspartates (Asp406 and Asp407, the DD 
motif) (Figure 1.1) (10). Mutations in the DD motif almost completely abolished the binding 
between hSesn2 and GATOR2 (10,20), suggesting that the DD motif constitutes a key protein-
protein interaction site. Importantly, mutations in the DD motif abolished both AMPK-activating 
and mTORC1-inhibiting functions of hSesn2 (10), signifying the importance of the DD motif and 
GATOR2 in Sestrin signaling. 
 
Sestrin as an amino acid sensor 
 Sestrin-null MEF or HEK293 cells, generated by triple knockout or knockdown of 
Sestrin1-3 genes, failed to downregulate mTORC1 activity after amino acid starvation (13,27). 
These observations implicated Sestrin in the amino acid-dependent control of mTORC1. 
Recently, two papers further suggested that hSesn2 acts as a direct sensor of leucine, based on 
the following observations: (i) hSesn2 physically binds to leucine at a Kd of 20μM (18), which 
is lower than that of leucyl tRNA synthetase (45μM) (64), (ii) leucine binding to hSesn2 changes 
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its melting temperature and prevents its binding to GATOR2 (18), (iii) crystal structure of 
hSesn2 was determined in the presence of added leucine, and leucine was found in a binding 
pocket in the crystal structure of hSesn2 (20), and (iv) wild-type hSesn2, but not leucine-binding 
defective hSesn2 mutants, restored the leucine sensitivity of mTORC1 signaling in Sestrin-null 
HEK293 cells (18,20). According to this model, hSesn2 cannot inhibit mTORC1 in the presence 
of leucine because leucine binding prohibits hSesn2 from interacting with its effector, GATOR2. 
 In addition to leucine, hSesn2 can also bind to other hydrophobic amino acids such as 
methionine, isoleucine and valine, although with a lower binding affinity (18). hSesn1 can also 
strongly bind to leucine while the binding between hSesn3 and leucine was found to be weak 
(Table 1.1) (18). On the other hand, all three Sestrin isoforms, hSesn1-3, can strongly bind to 
GATOR2 and inhibit mTORC1 (13-15). Although leucine was reported to disrupt the hSesn1-
GATOR2 and hSesn2-GATOR2 interactions, the hSesn3-GATOR2 interaction was not 
disrupted by the in vitro addition of leucine (18). 
 Although these are potentially important findings in the field of amino acid signaling, 
there are several caveats that need to be addressed before considering hSesn2 as an established 
leucine sensor. First, in contrast to the prediction that Sestrin2 is inactivated by leucine above 
20μM, numerous studies (8,10,12-15,22,23,27,61,65) indicated that hSesn2 is still able to 
suppress mTORC1 signaling in conditions rich with leucine. These conditions include 
conventional cell culture media such as RPMI and DMEM that contains 380μM and 800μM of 
leucine, respectively, and the intracellular amino acid concentration can be higher due to the 
presence of active transporters (66,67). Therefore, the effect of leucine on Sestrin2 function 
could be variable depending on the biological context. Second, in contrast to the theory that the 
hSesn2-GATOR2 interaction is completely disrupted by leucine (18,20), the physical interaction 
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between hSesn2 and GATOR2 was detectable in various cell lines cultured in leucine-rich 
conditions (13-15). Finally, although the leucine sensor model predicted that leucine binding and 
dissociation would induce large conformational changes in hSesn2 (18,20), the crystal structures 
determined in the presence or absence of leucine were actually quite similar (Figure 1.1) (10,20). 
Thus, whether hSesn2 is indeed inactivated by leucine binding under physiological conditions 
needs further clarification. 
 More recently, several additional mechanisms were suggested to explain the role of 
Sestrin2 in amino acid sensing. First, GCN2, an established sensor of amino acids (68), was 
shown to induce hSesn2 transcription through upregulation of the ATF4 transcription factor (28). 
The GCN2-dependent hSesn2 induction was important for mTORC1 regulation in response to 
amino acid availability, including leucine and glutamine (28). Second, it was also shown that 
Sestrin2 is phosphorylated by ULK1 in response to leucine starvation (69). Because 
phosphorylation may affect the leucine-binding or mTORC1-regulating activities of Sestrin2, 
further studies may clarify why different studies contradict each other in regards to whether 
physiological leucine concentrations can inhibit Sestrin2 function and/or Sestrin2-GATOR2 
binding. It is also worth noting that, in addition to being phosphorylated by ULK1, Sestrin2 can 
potentiate ULK1-dependent phosphorylation (47) and degradation (11) of SQSTM1. Considering 
that SQSTM1 was recently characterized as an important mTORC1 regulator that is involved in 
amino acid sensing (70-72), future studies are necessary to understand how Sestrin2, ULK1, 





Sestrin as an mTORC2 regulator 
 Even though Sestrin strongly suppresses mTORC1 signaling, Sestrin upregulated 
mTORC2-dependent AKT phosphorylation in cultured cells as well as in mouse and Drosophila 
tissues (16,17). Because chronic activation of mTORC1 and S6K signaling is known to cause 
insulin resistance (73), Sestrin-mediated mTORC2-AKT activation could be dependent on the 
mTORC1-suppressive activity of Sestrin. However, Sestrin-induced activation of the 
TSC1:TSC2 complex can also contribute to mTORC2 upregulation through an mTORC1-
independent mechanism (74). Recently, Sestrin2 and Sestrin3 were shown to physically bind to 
mTORC2 through Rictor, one of its regulatory subunits, and directly promote the catalytic 
activity of mTORC2 (16). Thus, it seems that Sestrin can upregulate mTORC2-AKT signaling 
through multiple mechanisms. The AKT-upregulating activities of Sestrin could be critical for 
its protection against insulin resistance and diabetic progression (16,17). Further investigation 
should be targeted towards defining a clear molecular mechanism for Sestrin-mediated AKT 
upregulation and defining the context-dependent contributions of the multiple signaling 
pathways. 
 
Concluding Remarks  
 In recent years, significant progress has been made towards understanding the biochemical 
mechanisms behind the actions of Sestrin; however, many questions still remain. Sestrin is a 
versatile protein that can single-handedly control a variety of anti-aging functions, which can be 
roughly classified into its ROS-reducing and mTOR-regulating functions. The recently determined 
crystal structure of hSesn2 supported this dual role by revealing two subdomains responsible for 
each of these functions. In addition, structure-guided mutagenesis studies generated a list of point 
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mutations that specifically ablate the redox-controlling or mTORC1-modulating functions of 
Sestrin (Table 1.2), which constitutes an essential toolkit for the molecular dissection of Sestrin 
function in diverse physiological contexts. Considering the important physiological functions of 
Sestrin in regulating metabolic homeostasis and attenuating age-associated pathologies, further 
investigation into the biochemical functions of Sestrin may generate novel insight into developing 
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The GATOR2-mTORC2 Axis Mediates Sestrin2-induced AKT Ser/Thr Kinase Activation 
 
Abstract 
Sestrins represent a family of stress-inducible proteins that prevent the progression of many 
age- and obesity-associated disorders. Endogenous Sestrins maintain insulin-dependent AKT 
Ser/Thr kinase (AKT) activation during high-fat diet (HFD)-induced obesity, and overexpressed 
Sestrins activate AKT in various cell types, including liver and skeletal muscle cells. Although 
Sestrin-mediated AKT activation improves metabolic parameters, the mechanistic details 
underlying such improvement remain elusive. Here, we investigated how Sestrin2, the Sestrin 
homolog highly expressed in liver, induces strong AKT activation. We found that two known 
targets of Sestrin2, mTOR complex 1 (mTORC1) and AMP-activated protein kinase (AMPK), are 
not required for Sestrin2-induced AKT activation. Rather, phosphoinositol-3-kinase (PI3K) and 
mTORC2, kinases upstream of AKT, were essential for Sestrin2-induced AKT activation. Among 
these kinases, mTORC2 catalytic activity was strongly upregulated upon Sestrin2 overexpression 
in an in vitro kinase assay, indicating that mTORC2 may represent the major link between Sestrin2 
and AKT. As reported previously, Sestrin2 interacted with mTORC2; however, we found here that 
this interaction occurs indirectly through GATOR2, a pentameric protein complex that directly 
interacts with Sestrin2. Deleting or silencing WD repeat domain 24 (WDR24), the GATOR2 
 
2 This chapter represents a published manuscript: Kowalsky AH*, Namkoong S*, Mettetal E, Park HW, Kazyken D, 
Fingar DC, Lee JH. The GATOR2-mTORC2 axis mediates Sestrin2-induced AKT Ser/Thr kinase activation. 
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component essential for the Sestrin2–GATOR2 interaction, or WDR59, the GATOR2 component 
essential for the GATOR2–mTORC2 interaction, completely ablated Sestrin2-induced AKT 
activation. We also noted that Sestrin2 directly binds to the pleckstrin homology (PH) domain of 
AKT and induces AKT translocation to the plasma membrane. These results uncover a signaling 
mechanism whereby Sestrin2 activates AKT through GATOR2 and mTORC2. 
 
Introduction  
Sestrins are highly conserved, stress-induced proteins with anti-aging properties in model 
organisms such as worms and flies (1,2). In the mammalian genome, three Sestrin paralogs 
(Sestrin1-3) exist (3). Sestrin proteins have two important functions: reducing reactive oxygen 
species (ROS) (4,5) and inhibiting mammalian target of rapamycin complex 1 (mTORC1) (1,6). 
Many studies have also shown that Sestrin2 is important for metabolic homeostasis, especially 
during nutritional overload. For example, Sestrin2 was required to maintain insulin sensitivity in 
the liver upon high fat diet (HFD)-induced dietary obesity and Lepob mutation-induced genetic 
obesity (7). Under lipotoxic conditions, Sestrin2 was selectively upregulated in the liver to 
alleviate endoplasmic reticulum (ER) stress by inhibiting mTORC1, thereby attenuating the 
development of steatohepatitis (8). Likewise, Sestrin3, another Sestrin paralog, is also expressed 
in the liver and upregulates the insulin-AKT signaling pathway during HFD and obesity (9). These 
metabolic studies revealed that, in addition to oxidative stress reduction and mTORC1 
downregulation, Sestrins also upregulate AKT signaling (7,9). Sestrin-induced AKT activation 
was also observed in Drosophila (7). 
The molecular structure of Sestrin2 revealed a structural basis for Sestrin2’s formerly 
characterized biochemical functions (5,10). A helix-turn-helix motif, composed of a proton relay 
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system and reactive Cys125, mediates the oxidoreductase function of Sestrin2 in reducing 
alkylhydroperoxides (5). The DD motif, composed of two adjacent Asp406 and Asp407 residues 
in a loop, was important for the interaction between Sestrin2 and GATOR2, a pentameric protein 
complex regulating mTORC1 signaling (5,10). Mutation in either of these two Asp residues 
nullifies Sestrin2’s ability to downregulate mTORC1 (5). Through the DD motif, Sestrin2 directly 
interacts with GATOR2 and releases it from inhibiting GATOR1, a trimeric protein complex with 
GTPase activity on the mTORC1-activating Rag proteins (5,11-13). Therefore, Sestrin2 inhibits 
mTORC1 by inhibiting GATOR2 and allowing GATOR1 to inhibit the Rag proteins (11-13). 
Although the detailed mechanism is yet to be elucidated, the Sestrin2-GATOR2 interaction was 
also critical for AMPK activation (5), which is also critical for Sestrin2-mediated mTORC1 
downregulation in many different cell types and physiological contexts (1,6,14-18). Therefore, it 
is possible that GATOR2 has functions outside of mTORC1 regulation, mediating Sestrin2 output 
to other effector molecules and target pathways. GATOR2 consists of five proteins: WDR24, 
WDR59, MIOS, SEH1L, and SEC13 (19). Among these components, WDR24 and SEH1L are 
critical for physically interacting with Sestrin2 (12). 
AKT is a major regulatory protein downstream of the insulin receptor that is responsible 
for many glucose and lipid regulating functions (20). Upon insulin stimulation, AKT is activated 
and phosphorylates a wide range of protein substrates to inhibit gluconeogenesis and upregulate 
glycogenesis and lipogenesis. In addition to its metabolic regulation, AKT also promotes cell 
growth and proliferation and is implicated in many cancers. AKT has two active phosphorylation 
sites, Thr308 and Ser473, which are phosphorylated by phosphoinositide-dependent kinase 1 
(PDK1) and mTORC2, respectively. Upon activation of the insulin signaling cascade leading to 
phosphoinositol-3-kinase (PI3K) activation, a second messenger phosphatidylinositol 3, 4, 5-
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triphosphate (PI(3,4,5)P) accumulates in the plasma membrane, which recruits PDK1, mTORC2 
and AKT and induces PDK1 and mTORC2 to phosphorylate and activate AKT (20). 
Sestrin-induced AKT activation was observed in a variety of cellular and physiological 
contexts, in addition to the insulin resistance and obesity contexts (7,9). For instance, Sestrins have 
been shown to positively regulate AKT in cancer cells to protect against environmental stress, such 
as UV irradiation, energetic stress and chemical stress (21-25). Sestrins are also important for 
muscle AKT activation, and the Sestrin-dependent AKT regulation is critical for producing 
exercise benefits and preventing age- and disuse-associated atrophy (26,27). There have been 
several mechanisms proposed to explain Sestrin-induced AKT activation. The first is that Sestrin-
induced mTORC1 inhibition releases the insulin receptor signaling pathway from mTORC1/S6K-
mediated negative feedback inhibition (28). In this model, chronic mTORC1 activation induces 
S6K-dependent insulin receptor substrate (IRS) serine phosphorylation, which attenuates signal 
transduction from the insulin receptor to PI3K (29). Therefore, Sestrin-mediated mTORC1 
inhibition can indirectly upregulate PI3K-AKT signaling (28). Consistent with this model, loss of 
Sestrin2 upregulated S6K-mediated inhibitory serine phosphorylation of IRS while 
downregulating insulin receptor-mediated activatory tyrosine phosphorylation (7). In addition to 
the S6K-mediated feedback, Sestrin may also downregulate additional pathways that lead to 
insulin resistance, such as ER stress (8) and inflammation pathways (30). Furthermore, several 
recent studies also suggested that Sestrin-dependent AKT activation could be independent of 
mTORC1 and directly through mTORC2 (9,23). Still, the mechanistic details of how Sestrin2 
regulates AKT remain incompletely understood. 
In this study, we investigated the molecular mechanism by which Sestrin2 induces AKT 
activation in liver cells. We found that GATOR2 and mTORC2 link Sestrin2 to AKT activation. 
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This new mechanism explains, at least in part, how Sestrin2 promotes metabolic homeostasis 
through increased AKT activity. 
 
Results 
Sestrin2 overexpression improves glucose and lipid regulation in HFD mice 
Extensive studies have established that endogenous Sestrins protect against obesity-
associated fatty liver and insulin resistance (7-9,28). Based on these findings, we tested if Sestrin2 
overexpression could improve metabolic regulation in obese WT mice under HFD conditions. For 
this, adenoviruses expressing GFP (Ad-GFP) or Sestrin2 (Ad-SESN2) were administered to 
weight and age-matched mice through tail vein injections. Strikingly, after adenoviral expression 
of Sestrin2, both basal and insulin-reduced blood glucose levels were strongly decreased (Figure 
2.1A), and HFD-induced lipid accumulation in the liver tissue was also strongly decreased (Figure 
2.1B). Nevertheless, Ad-SESN2 transduction did not substantially change overall body weight 
(Figure 2.1C). Consistent with reduction in blood glucose (Figure 2.1A) and liver fat levels (Figure 
2.1B), mRNA expression of gluconeogenic and lipogenic genes were strongly decreased by 
Sestrin2 overexpression (Figure 2.1D). Therefore, the evidence suggests that Sestrin2 
overexpression in liver was sufficient to alter hepatic transcription of metabolic genes and 
subsequently restore glucose and lipid homeostasis in obese, insulin-resistant mice. 
 
Sestrin2 overexpression induces strong AKT activation in mouse liver and HepG2 cells 
Upon examining liver lysates obtained from HFD-fed mice, we found that overexpression 
of Sestrin2 increased AKT phosphorylation on both the PDK1-mediated activation loop site (T308) 




Figure 2.1. Sestrin2 overexpression improves glucose and lipid homeostasis in HFD mice. 
Two-month-old C57BL/6J mice were fed a high fat diet (HFD) for at least two additional months. 
Mice were then administered tail vein injections of adenoviruses (109 pfu) that express GFP (Ad-
GFP; n=13) or Sestrin2 (Ad-SESN2; n=12). (A) Four to ten days after adenovirus administration, 
mice were fasted for six hours then subjected to insulin tolerance tests (ITT, 0.65U/kg). (B) Fresh 
frozen liver sections were stained with Oil Red O (ORO) and quantified (n=6) to determine fat 
accumulation in liver tissue. Scale bar, 200 µm (C) Body weights of animals at ten days after 
adenovirus administration. (D) Liver lysates were analyzed by quantitative RT-PCR to examine 
expression of metabolism-regulating genes in the liver tissue (n=6). Data are presented as mean ± 
SEM. P-values were calculated between Ad-GFP and Ad-SESN2 groups from a two-tailed 



















































strong AKT activation. In fact, Sestrin2 increased phosphorylation on these sites to a level higher 
than that mediated by acute insulin treatment of control mice (Figure 2.2A). Moreover, Sestrin2 
overexpression increased basal liver AKT phosphorylation strongly in HFD-fed mice (Figure 2.2A) 
and consistently increased AKT phosphorylation in HepG2 cells (Figure 2.2B). However, unlike 
in the liver where the effect of Sestrin2 on AKT phosphorylation was stronger than insulin (Figure 
2.2A), the effects of Sestrin2 and insulin on AKT phosphorylation were additive in HepG2 cells 
(Figure 2.2B). Sestrin2 overexpression also rescued AKT phosphorylation in the presence of 
inhibitory palmitic acid (PA) treatment, a saturated fatty acid that produces strong cellular insulin 
resistance (31) (Figure 2.2B, 2.2C). Conversely, silencing Sestrin2 in HepG2 cells decreased AKT 
phosphorylation in both normal and PA-treated conditions (Figure 2.2C). 
 
Sestrin2 overexpression upregulates AKT independently of mTORC1 and AMPK 
Because Sestrin2 inhibits mTORC1 and thus suppresses mTORC1/S6K1-meditated 
negative feedback on insulin signaling and PI3K flux, it was possible that Sestrin2 activates AKT 
indirectly through this negative feedback mechanism (29) (Figure 2.2D). To test whether 
mTORC1 inhibition mediates Sestrin2-induced AKT activation, we transduced HepG2 cells with 
increasing dosages of Sestrin2 and co-treated the cells with rapamycin, an mTORC1-specific 
inhibitor. As expected, Sestrin2 dose-dependently activated AKT in HepG2 cells (Figure 2.2E). 
Interestingly, Sestrin2-induced AKT activation was still observed in rapamycin-treated cells, in 
which mTORC1-dependent S6K1 phosphorylation was completely blocked (Figure 2.2E), 




Figure 2.2. Sestrin2 activates AKT independently of mTORC1 and AMPK. (A) At 10 days 
after Ad-GFP or Ad-SESN2 administration, mouse livers were collected before (-) and 10 min 
after (+) an injection of insulin (0.8U/kg). Liver lysates were analyzed by immunoblotting. (B-C) 
HepG2 cells were treated with bovine serum albumin (BSA) loaded with palmitic acid (PA, 
500µM) for 9 hours, then treated with insulin (+, 50 nmol) for 20 min. BSA-only and water-only 
(-) samples were used as controls. (B) HepG2 cells were acutely infected with control or Sestrin2-
overexpressing adenoviruses before BSA and PA treatments. (C) HepG2 cells were stably infected 
with control (shRNA-Luciferase) and shRNA-SESN2 lentiviruses before BSA and PA treatments. 
All samples were analyzed by immunoblotting. (D) Schematic of potential molecular mechanisms 
that can account for Sestrin2-induced AKT activation. (E) HepG2 cells were infected with Ad-
GFP or Ad-SESN2 for 12 hours, serum starved with or without rapamycin (Rapa, 10nM) for 24 
hours, and subjected to immunoblotting. (F) WT and Ampkα1-/-/Ampkα2-/- mouse embryonic 
fibroblasts (MEFs) were serum starved in DMEM with 0.1% FBS and treated with Ad-GFP or Ad-
















Fig. 2: Kowalsky et al.
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feedback loop (Figure 2.2D). More recently, it was reported that AMPK promotes mTORC2 
signaling in response to acute energetic stress through phosphorylation of mTOR and mTORC2 
partner proteins (32). As Sestrin2 activates AMPK, it was possible that Sestrin2 increases 
mTORC2-mediated AKT phosphorylation and activation through AMPK (Figure 2.2D). To 
determine if Sestrin2-induced AKT activation was occurring through AMPK, we treated wild-type 
and AMPK-null mouse embryonic fibroblasts (WT and Ampkα1-/-/Ampkα2-/- DKO MEFs) with Ad-
SESN2. As observed in HepG2 cells, Sestrin2 still activated AKT in both WT and AMPKα1/2 DKO 
MEFs, indicating that this regulation was independent of AMPK (Figure 2.2F). These results 
reveal a novel mechanism by which Sestrin2 induces AKT activation independently of mTORC1 
and AMPK, two established effectors of Sestrin2. 
 
PI3K and mTORC2 are required for Sestrin2-induced AKT activation 
To further investigate the mechanism by which Sestrin2 activates AKT, we treated HepG2 
cells with a panel of chemical inhibitors specific for signaling components that regulate AKT 
(Figure 2.3A). BYL719, a PI3K-specific inhibitor, and Torin1, an active site mTOR inhibitor 
(inhibits both mTORC1 and mTORC2), completely ablated Sestrin2-induced AKT activation 
(Figure 2.3B), indicating that both PI3K and mTOR, specifically mTORC2, are required for 
Sestrin2-induced AKT activation. Consistent with this, LY294002, an inhibitor of both PI3K and 
mTOR, and PP242, another active site mTOR inhibitor, also blocked Sestrin2-induced AKT 
activation (Figure 2.3C). Therefore, these data suggest that both PI3K and mTORC2 activities are 





Figure 2.3. Sestrin2 upregulates mTORC2. (A) Schematic of AKT-regulating pathways and 
drugs targeting the pathway. (B-C) HepG2 cells were treated with Ad-GFP or Ad-SESN2, serum 
starved and treated with DMSO (Con), BYL719 (10nM), Torin1 (200nM), LY294002 (20µM), or 
PP242 (5µM), then analyzed by immunoblotting. (D-E) HepG2 cells infected with Ad-GFP or Ad-
SESN2 were stimulated with or without insulin (100nM). (D) Lysates were subjected to 
phosphotyrosine (p-Tyr) immunoprecipitation, and subjected to a lipid kinase assay with γ-32P-
ATP and phosphotidylinositol, then subjected to thin layer chromatography and autoradiography 
to visualize radiolabeled PI3P. (E) Lysates were subjected to anti-Rictor immunoprecipitation, and 
subjected to an in vitro kinase assay using ATP and recombinant full-length inactive His-AKT. 
The reaction mixtures, as well as original whole cell lysates (WCL) were subjected to subsequent 























































































































Sestrin2 upregulates the catalytic activity of mTORC2 but not PI3K  
Because both PI3K and mTORC2 were required for Sestrin2-induced AKT activation, we 
assessed the effect of Sestrin2 on these signaling components through in vitro kinase assays. 
Although the established PI3K activator insulin was able to prominently increase the lipid kinase 
activity of PI3K, Sestrin2 did not have a measurable effect on PI3K activity in basal serum-starved 
conditions (Figure 2.3D). In contrast, both insulin and Sestrin2 had a strong positive effect on the 
catalytic activity of mTORC2 in phosphorylating AKT (Figure 2.3E). Sestrin2-induced mTORC2 
activation can lead to AKT S473 phosphorylation, which can subsequently facilitate PDK1-
mediated AKT T308 phosphorylation (33). Therefore, our data suggest that Sestrin2 acts through 
mTORC2 to activate AKT. 
 
The GATOR2-binding function of Sestrin2 is required for AKT activation 
We next investigated the biochemical basis of how Sestrin2 upregulates mTORC2 and 
AKT. To address this problem, we utilized point mutants of Sestrin2 that specifically eliminate 
either its redox-regulating or GATOR2-binding functions (34). Like wild-type Sestrin2, Cys125-
mutated Sestrin2 with no oxidoreductase activity (5) strongly upregulated mTORC2-dependent 
AKT phosphorylation as well as AKT-dependent phosphorylation of its substrates FOXO1 and 
SIN1 (Figure 2.4A). In contrast, Asp406- and Asp407-mutated Sestrin2, which cannot bind to the 
GATOR2 complex (5), was unable to upregulate the AKT signaling pathway (Figure 2.4A). These 
results suggest that the GATOR2-binding motif of Sestrin2, but not the redox-regulating motif, is 




Figure 2.4. Sestrin2 requires GATOR2 to activate AKT. (A) HepG2 cells were infected with 
lentiviruses (LV) that express control (GFP), wild-type (WT), or single residue mutant forms of 
Sestrin2 (D406A, D407A, C125S), serum starved and subjected to immunoblotting. (B) HepG2 
cells expressing control (pLKO-Con) or WDR24 (pLKO-WDR24) shRNA were treated with Ad-
GFP or Ad-SESN2, serum starved, then subjected to immunoblotting. (C) HepG2 cells were 
subjected to control (EGFP) or WDR24 gene knockout targeting using CRISPR/Cas9. Cells with 
confirmed knockouts were then treated with Ad-GFP or Ad-SESN2, serum starved, then subjected 
to immunoblotting. (D) Primary hepatocytes were isolated from Con (Wdr24f/f) or liver-specific 
Wdr24-knockout (Wdr24 LKO; Wdr24f/f/Alb-Cre) livers, treated with Ad-GFP or Ad-SESN2, 
serum starved for 3 hours, then subjected to immunoblotting. (E-G) Two-month-old Wdr24 LKO 
mice were fed a HFD for two additional months, administered tail vein injections of Ad-GFP (n=5) 
or Ad-SESN2 (n=7). (E) Wdr24 LKO mice were subjected to an ITT 7 days after adenovirus 
administration. (F) Area under curve (AUC) was calculated for the ITT. WT data are from Figure 
1A. (G) Livers were collected before (-) or 5 min after (+) an injection of insulin (0.8U/kg), and 
their lysates were analyzed by immunoblotting. Data are presented as mean ± SEM. P-values were 
calculated between control (Ad-GFP) and Sestrin2 overexpressing (Ad-SESN2) groups from a 


























































































Fig. 4: Kowalsky et al.





































































GATOR2 is required for Sestrin2-induced AKT activation 
WDR24 is a GATOR2 component that is essential for the Sestrin2-GATOR2 interaction 
(12). To directly assess the requirement of GATOR2 in Sestrin2-induced AKT activation, we 
ablated WDR24 function through both gene silencing and knockout methods. In HepG2 cells, 
shRNA-mediated WDR24 silencing (Figure 2.4B) and CRISPR/Cas9-mediated WDR24 knockout 
(Figure 2.4C) eliminated Sestrin2-induced AKT activation. Likewise, hepatocytes isolated from 
liver-specific Wdr24-knockout (Wdr24 LKO) mice failed to increase AKT activation after Sestrin2 
overexpression (Figure 2.4D). Consistent with the requirement for WDR24 in Sestrin2-induced 
AKT activation, HFD-fed obese Wdr24 LKO mice did not reduce blood glucose levels (Figure 
2.4E, 2.4F) or increase hepatic AKT signaling (Figure 2.4G) in response to Ad-SESN2 
transduction, unlike HFD-fed obese wild-type mice (Figure 2.1A, 2.2A, 2.4G). Notably, Wdr24 
LKO mice retained insulin-induced AKT upregulation (Figure 2.4G), indicating that WDR24 is 
not required for insulin signaling to AKT but is required for Sestrin2-induced AKT activation. 
Taken together, these data indicate that Sestrin2 requires GATOR2 to activate AKT and improve 
metabolic phenotypes in HFD mice. 
 
GATOR2 physically bridges Sestrin2 and mTORC2 
To identify Sestrin2 targets in HepG2 cells, we performed proteomic analysis of Sestrin2-
interacting proteins in HepG2 cells. Consistent with previous studies of the Sestrin2 interactome 
analyzed from MCF10A cells (12,13) and HEK293T cells (11), the GATOR2 components 
appeared among the top Sestrin2 interacting proteins in HepG2 cells (Table 2.1). Based on the 
genetic requirement of GATOR2 in Sestrin2-induced AKT activation (Figure 2.4), and the 
physical association between Sestrin2 and GATOR2 in HepG2 cells (Table 2.1), we hypothesized 
 40 
that GATOR2 may be the molecular conduit for Sestrin2-mediated upregulation of mTORC2 and 
subsequent AKT activation. Recent reports showed that Sestrin2 physically associates with 
mTORC2 (9,23), and consistent with this, we were able to replicate the interaction between 
Sestrin2 and Rictor, an mTORC2-specific protein (Figure 2.5A). Interestingly however, Sestrin2 
mutants that cannot bind GATOR2 (e.g. Asp406Ala and Asp407Ala) lost the ability to bind Rictor 
(Figure 2.5A). In contrast, the Cys125-mutated Sestrin2 fully retained Rictor-binding, indicating 
that the redox-regulating function of Sestrin2 is not required for the Sestrin2-mTORC2 interaction.  
These findings raised the possibility that GATOR2 bridges Sestrin2 and mTORC2. We 
therefore examined whether mTORC2 associates with GATOR2 through co-immunoprecipitation 
assays between Rictor and GATOR2 components. In addition to testing the interaction with the 
full complex, we systematically deleted subcomponents of GATOR2 or systematically expressed 
single components of GATOR2, to identify the GATOR2 subcomponent(s) that are responsible 
for the GATOR2-Rictor interaction. Interestingly, we found that GATOR2 and Rictor interact 
(Figure 2.5B, blue boxes), and moreover, the WDR59 subcomponent of GATOR2 was critical and 
sufficient for this interaction. When WDR59 was not expressed, the interaction between Rictor 
and GATOR2 was very weak (Figure 2.5B, red box in left panel), and WDR59 alone pulled down 
Rictor (Figure 2.5B, red box in right panel). Previous work showed that WDR24 is critical for the 
Sestrin2-GATOR2 interaction (12), and our current work identifies WDR59 as a critical 
component for the GATOR2-Rictor interaction (Figure 2.5C). These data suggest that Sestrin2 
and Rictor interact through GATOR2, containing both WDR24 and WDR59. Indeed, like WDR24, 
WDR59 was also required for Sestrin2-induced AKT activation; Sestrin2 failed to upregulate AKT 
in WDR59 knockout (KO) HepG2 cells generated through CRISPR targeting (Figure 2.5D). In 
addition, we confirmed the GATOR2-mTORC2 interaction through showing that Sin1, another 
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SESN2 59 54 85.00% P58004 
TJAP1 14 14 31.80% Q5JTD0-1 
MIOS 13 13 21.11% Q9NXC5-1 
GMPPB 12 12 47.55% Q9Y5P6-2 
ASB1 6 6 25.07% Q9Y576 
SEH1L 6 6 20.43% Q96EE3-1 
WDR59 4 4 7.39% Q6PJI9-1 
RMDN1 4 4 12.10% Q96DB5 
AMMECR1 4 4 15.62% Q9Y4X0 
LGALS3 3 3 14.40% P17931 
WDR24 3 3 4.57% Q96S15-1 
 
The number of peptide hits for Sestrin2 and its ten strongest interacting partners, among which 
four are GATOR2 components (shaded in grey). The full mass-spectrometry proteomics data is 












Figure 2.5. GATOR2 physically bridges Sestrin2 and mTORC2. (A-B) HEK293 cells were 
transfected with indicated constructs for 48 hours then subjected to co-immunoprecipitation (IP) 
with indicated antibodies. IP complexes and whole cell lysates (WCL) were examined through 
immunoblotting. (C) Schematic of how GATOR2 interacts with Sestrin2 and mTORC2. WDR24 
was critical for the Sestrin2-GATOR2 interaction, while WDR59 was critical for the GATOR2-
Rictor interaction. (D) HepG2 cells stably expressing control (WT) or WDR59-targeting 
CRISPR/Cas9 constructs were infected with Ad-GFP or Ad-SESN2, serum starved overnight, then 
subjected to immunoblotting. (E) HEK293 cells were transfected with indicated constructs for 48 
hours then subjected to IP with indicated antibodies. IP complexes and WCL were examined 
through immunoblotting. (F) HepG2 cells were subjected to anti-IgG or anti-Rictor IP overnight. 
IP complexes and WCL were examined through immunoblotting of endogenous proteins. 
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critical mTORC2-specific subcomponent, also interacted with the full GATOR2 complex (Figure 
 2.5E). Finally, we also observed Rictor-Sestrin2 and Rictor-WDR59 interactions at the 
endogenous level in HepG2 cells (Figure 2.5F). These data collectively suggest that GATOR2 
bridges Sestrin2 and mTORC2 to enable Sestrin2-mediated activation of mTORC2 and AKT 
(Figure 2.5C). 
 
Sestrin2 directly binds to the PH domain of AKT 
While examining the physical interaction between Sestrin2 and other proteins, we 
serendipitously found that overexpressed Flag-tagged Sestrin2 pulls down endogenous AKT in 
liver tissue (Figure 2.6A). The Sestrin2-interacting AKT proteins were phosphorylated at both 
Thr308 and Ser473 (Figure 2.6A), suggesting that these are active AKT proteins. The Sestrin2-
AKT interaction was also observable in HEK293A cells (Figure 2.6B); interestingly, Sestrin2 
mutants that cannot bind GATOR2 were still able to interact with AKT (Figure 2.6B). Therefore, 
it seems that the Sestrin2-AKT interaction is independent of the interactions we observed above 
for the Sestrin2-GATOR2-mTORC2 complexes.  
To dissect the interaction between Sestrin2 and AKT further, we transfected Sestrin2 with 
three different forms of AKT: full-length, PH domain only (F-AKT_PH: residues 1-149), or kinase 
domain only (F-AKT_KD: residues 150-480) truncated forms (Figure 2.6C). Using an 
immunoprecipitation assay, we confirmed that Sestrin2 physically interacted with full-length AKT. 
Sestrin2 also slightly interacted with AKT_KD, but we found the strongest association with 
AKT_PH, the truncated form of AKT that includes the PH domain only (Figure 2.6C). Therefore, 




Figure 2.6. Sestrin2 induces AKT translocation to the plasma membrane. (A) Liver lysates 
from Ad-GFP and Ad-SESN2 infected mice, described in Figure 1, were subjected to anti-Flag 
immunoprecipitation (IP). IP complexes and whole cell lysates (WCL) were examined through 
immunoblotting. (B-C) HEK293 cells were transfected with indicated constructs for 24 hours then 
subjected to IP with indicated antibodies. IP complexes and WCL were examined through 
immunoblotting. (D) HepG2 cells were infected with Ad-GFP or Ad-SESN2, serum starved 
overnight, then analyzed by immunocytochemistry using indicated antibodies. (E-H) HepG2 cells 
were infected with Ad-GFP or Ad-SESN2, serum starved overnight, then subjected to membrane 
fractionation experiments and subsequent immunoblotting. (F) Membrane fractions for indicated 
proteins were quantified by densitometry (n=3). (G) WDR24 and WDR59 were targeted using 
CRISPR/Cas9 in HepG2 cells. Cells with confirmed knockouts were subjected to indicated 
treatments, membrane fractionation then immunoblotting. (H) Relative AKT protein expression 
was quantified by densitometry for membrane fractions (n≥3). P-values were calculated between 
control (Ad-GFP) and Sestrin2 overexpressing (Ad-SESN2) membrane fractions from a two-tailed 
student’s t-test: *p<0.05, **p<0.01.  
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important for AKT translocation to the plasma membrane through binding 3’ phosphorylated 
phosphoinositide lipids generated by PI3K (20). 
 
Sestrin2 induces AKT plasma membrane translocation through GATOR2 
We were curious if the interaction between Sestrin2 and the PH domain of AKT could alter 
the subcellular localization of AKT. In serum-starved HepG2 cells, Sestrin2 overexpression 
through adenoviral transduction induced strong AKT activation at the plasma membrane (Figure 
2.6D). Total AKT was also generally translocated to the plasma membrane in Sestrin2 
overexpressing cells (Figure 2.6D).  The Sestrin2-induced membrane localization of AKT also 
occurred in cell fractionation experiments; Sestrin2 overexpression increased the presence of both 
p-AKT and AKT in total membrane fractions (Figure 2.6E, 2.6F). Interestingly, the GATOR2 
components WDR24 and WDR59 were also targeted to the membrane fraction upon Sestrin2 
overexpression (Figure 2.6E, 2.6F). Therefore, we tested if Sestrin2-induced AKT membrane 
translocation required GATOR2. WDR24 KO and WDR59 KO HepG2 cells, in which GATOR2 
function is compromised, did not target AKT to the membrane fraction in response to Sestrin2 
overexpression (Figure 2.6G, 2.6H). Therefore, even though Sestrin2 binding to AKT may not 
require GATOR2, GATOR2 is required for Sestrin2-induced AKT activation and its translocation 
to the plasma membrane. 
 
Discussion 
Insulin resistance represents one of the most prominent phenotypes exhibited by Sestrin-
deficient animals (28). Sesn2-knockout mice (7) and Sesn3-knockout mice (9,35), as well as dSesn-
null flies (7), are all prone to developing insulin resistance and subsequent dysregulation of blood 
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glucose homeostasis. Hypoactivity of insulin receptor-AKT signaling is commonly observed in 
these models, while mTORC1 signaling was aberrantly activated through a mechanism 
independent of insulin signaling regulation. As Sestrins downregulate mTORC1, it was thought 
that mTORC1 inhibition was the major cause of AKT upregulation (28). However, Sestrin-induced 
AKT activation was observed when mTORC1 components were silenced or ablated (9,23), 
suggesting that Sestrins may regulate AKT independently of mTORC1. Consistent with these 
reports, we confirmed that Sestrin2-induced AKT activation did not require mTORC1. Instead, 
Sestrin2 activated AKT by upregulating mTORC2, a kinase upstream of AKT. Therefore, our 
results indicate that Sestrin2 not only suppresses mTORC1 but concurrently activates mTORC2, 
a finding that aligns with other work indicating that tuberous sclerosis complex (TSC) and AMPK 
inhibit mTORC1 but activate mTORC2 (32,36,37). 
We also defined the molecular mechanism by which Sestrin2 upregulates mTORC2. 
AMPK was recently shown to upregulate mTORC2 activity and signaling  independently of 
mTORC1/S6K1-mediated negative feedback through direct phosphorylation of mTORC2 subunits 
(32). Since Sestrin2 represents an established AMPK activator (3), it was possible that 
Sestrin2/AMPK signaling mediates  Sestrin2-induced mTORC2 activation. However, we found 
that Sestrin2 activated mTORC2 and AKT similarly in wild type and Ampk-null cells, indicating 
that Sestrin2-induced mTORC2 activation could occur independently of AMPK. 
Utilizing mutational studies, we showed that Sestrin2’s GATOR2-binding residues were 
required for its activation of mTORC2 and AKT. Consistent with former studies reporting a direct 
interaction between Sestrin2 and mTORC2 (9,23), we found a physical association between 
Sestrin2 and Rictor, an mTORC2-specific subunit. However, Sestrin2 mutants that lost GATOR2 
binding were not able to interact with Rictor. Subsequent experiments suggested that GATOR2 
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acted as a bridge between Sestrin2 and mTORC2; GATOR2 interacts with Sestrin2 through 
WDR24 (12) and with mTORC2 through WDR59. Indeed, Sestrin2 was unable to upregulate 
mTORC2 and AKT in cells with genetic deletion of either WDR24 or WDR59. These experiments 
showed that GATOR2 mediates Sestrin2-induced activation of mTORC2 and AKT. Finally, our 
data suggested that Sestrin2 affects AKT subcellular localization. Through both 
immunocytochemistry and fractionation experiments, we found that Sestrin2 overexpression 
enriched both pAKT and AKT at the membrane. Since Sestrin2, WDR24/WDR59 and AKT are 
all enriched in the membrane fraction in conditions of Sestrin2 overexpression, it is possible that 
Sestrin2-GATOR2 complexes somehow physically direct AKT translocation. However, it is also 
possible that Ser473 phosphorylation, which is dependent on GATOR2-mTORC2, somehow 
promotes membrane translocation and further activation of AKT. The exact mechanism of how 
Sestrin2-GATOR2 induces membrane translocation and activation of AKT needs to be further 
clarified in future studies. 
Importantly, the unique ability of Sestrin2 to inhibit mTORC1, activate AMPK, and 
activate mTORC2 makes it an ideal candidate for extending an organism’s life and health span. 
While the mTORC1 inhibitor rapamycin extended lifespan in multiple animal models (38), it also 
coincided with serious side effects such as insulin resistance caused by suppression of mTORC2 
assembly and thus function (39). Although chronic mTORC1 upregulation is detrimental and 
accelerates aging, mTORC2 activity is required to maintain metabolic homeostasis because it is 
essential for insulin-dependent signal transduction. Therefore, many aging researchers have 
searched for genetic and pharmacological agents that specifically inhibit mTORC1 while 
preserving mTORC2 activity (40). Sestrin2 or its chemical mimetics may be candidates for such 
agents. 
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In addition, unlike other pathways that activate AKT (i.e. insulin), Sestrin2-induced AKT 
activation did not concurrently activate mTORC1. AKT typically upregulates mTORC1 through 
inhibitory phosphorylation of the mTORC1 inhibitors TSC2 (41) and PRAS40 (42,43). Therefore, 
although forced AKT activation in the liver through PTEN inactivation (44) or constitutively active 
AKT (myr-AKT) expression (45) upregulated insulin signaling, it also detrimentally 
hyperactivated mTORC1, resulting in hepatomegaly and hepatic fat accumulation. Even though 
Sestrin2 activated AKT, it did not upregulate mTORC1 because it has an independent inhibitory 
function on mTORC1. Therefore, unlike other models of AKT activation, Sestrin2 reduced liver 
fat accumulation while upregulating insulin signaling. Consistent with these functional outcomes, 
Sestrin2 inhibited mRNA expression of both gluconeogenic and lipogenic genes. 
In summary, we show that Sestrin2 upregulates the mTORC2/AKT pathway through a 
novel mechanism involving the GATOR2 complex. Further investigation into this signaling axis 
may reveal a novel mechanism for improving insulin signaling and normalizing metabolism during 
obesity and insulin resistance. 
 
Experimental Procedures 
Mice and Diets 
Wdr24f/f (Wdr24tm1c)/Alb-Cre strain was generated from the Wdr24tm1a(KOMP)Mbp mouse line 
obtained from the UC Davis Mouse Biology program by breeding with the FLPo strain, 
backcrossed into the C57BL/6J background, and then crossed with the Alb-Cre line. Two-month-
old WT or Wdr24f/f/Alb-Cre mice of the C57BL/6J background were kept on a high fat diet (HFD, 
Bioserv S3282) for two additional months. Insulin tolerance tests were performed on 25 WT mice 
and 12 Wdr24f/f/Alb-Cre mice. In each cohort, littermate mice were divided into two groups and 
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injected with adenoviruses through the tail vein. The insulin tolerance test (ITT) was performed at 
4-10 days after adenoviral injection. For the ITT, mice were fasted for 4-6 hours in the morning, 
then injected with insulin (0.65 U/kg body weight i.p.). Blood glucose was measured 0, 20, 40, 60, 
and 120 min after insulin injection using a OneTouch Ultra glucose meter. At 10 days after 
adenoviral injection, livers were harvested under a surgical plane of isoflurane anesthesia before 
and after an injection of insulin (0.8 U/kg) through the inferior vena cava. All mice were housed 
at the Unit for Laboratory Animal Medicine (ULAM), and all procedures were approved by the 
Institutional Animal Care & Use Committee (IACUC) at the University of Michigan. 
 
Oil Red O Staining 
Optimum cutting temperature compound (OCT)-embedded frozen liver sections were air 
dried and rinsed with 60% isopropanol, followed by staining with fresh 0.5% Oil Red Solution for 
15 min. After staining, slides were rinsed with 60% isopropanol, washed with distilled water, 
mounted and analyzed under a light microscope (Olympus). For quantification, 10 randomly 
chosen fields were used for each mouse liver. 
 
Quantitative reverse-transcription PCR 
Total RNA was extracted from tissues using Trizol (Invitrogen), and cDNA was made 
using MMLV-RT (Thermo fisher 28025013) and random hexamers (Invitrogen). Quantitative 
PCR was performed in a Real-Time PCR detection system (Applied Biosystems) with iQ SYBR 
Green Supermix (Bio-Rad) and primers listed in Table 2.2. Relative mRNA expression was 
calculated from the comparative threshold cycle (Ct) values normalized to β-actin and expressed 
as fold change over control values. 
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Table 2.2.  Chapter 2 qPCR Primers 
 
Gene Primer sequence 
G6pc F CTGCAAGGGAGAACTCAGCAA 
G6pc R GAGGACCAAGGAAGCCACAAT 
Pck1 F GTGTCATCCGCAAGCTGAAG 
Pck1 R CTTTCGATCCTGGCCACATC 
Hk1 F CACCGGCAGATTGAGGAAAC 
Hk1 R CTCAGCCCCATTTCCATCTCT 
Hk2 F GGAACCCAGCTGTTTGACCA 
Hk2 R CAGGGGAACGAGAAGGTGAAA 
G6pdx F GGCAAGCTCCTCAAAACTTG 
G6pdx R AGAGCCCCCAAAATATTGCT 
Fasn F GGCATCATTGGGCACTCCTT 
Fasn R GCTGCAAGCACAGCCTCTCT 
Acaca F GCCATTGGTATTGGGGCTTAC 
Acaca R CCCGACCAAGGACTTTGTTG 
Acacb F CATACACAGAGCTGGTGTTGGACT 
Acacb R CACCATGCCCACCTCGTTAC 
Actb F CAAAAGCCACCCCCACTCCTAAGA 
Actb R GCCCTGGCTGCCTCAACACCTC 
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Antibodies and Reagents 
Sestrin2 (10795) is from Proteintech. pT308-Akt (4056), pS473-Akt (4060), Akt (4691), 
pT389-S6K (9234), pT172-AMPK (2535), AMPKɑ (2532), mTOR (2983), Rictor (2114), 
WDR59 (53385), pS256-FOXO1 (9461), FOXO1 (2880), pT86-Sin1 (14716), Sin1 (12860), 
NaKATPase (23565), and Raptor (2280) are from Cell Signaling Technology. MAPKAP-1 
(393166), WDR24 (244614), p70S6 kinase ɑ (8418), and Rictor (271081) are from Santa Cruz 
Biotechnology. Flag (M2) is from Sigma. HA (3F10) is from Roche. Actin (JLA20), His (P5A11), 
Tubulin (E7), and c-Myc (9E10) are from Developmental Studies Hybridoma Bank (DSHB). 
Chemical inhibitors used in this study include rapamycin (LC Labs), BYL719 (Selleck), PP242 
(Chemdea), Torin1 (Adooq), and LY294002 (LC Labs). 
 
Western Blotting 
Cells or tissues were lysed in cell lysis buffer (20mM Tris-Cl, pH 7.5, 150mM NaCl, 1mM 
EDTA, 1mM EGTA, 2.5mM sodium pyrophosphate, 1mM ß-glycerophosphate, 1mM Na3VO4, 
1% Triton-X-100 or 1% NP-40 or 0.3% Chaps) containing protease inhibitor cocktail (Roche). 
After clarification by centrifugation, lysates were boiled in SDS sample buffer, separated by SDS-
PAGE, transferred to polyvinylidene difluoride membranes and probed with indicated antibodies. 
Primary antibody dilution factors were 1:200 for Santa Cruz antibodies and 1:1000 for all others. 
After incubation with secondary antibodies conjugated with HRP at 1:2000, chemiluminescence 
was detected using LAS4000 (GE) system. All protein loading was normalized to total protein 
concentration determined using Biorad Protein Assay (Biorad 5000006). Protein expression in 
membrane fractions were normalized by the level of NaKATPase. Primary antibodies were 
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incubated in western blocking reagent (11921681001, Sigma Aldrich) for phospho-specific 
antibodies or 5% blotting grade blocker (Bio-Rad 1706404) for all other antibodies.  
 
Cell Culture and Transfection 
All cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) 
containing 10% fetal bovine serum (Sigma), 20 U/ml penicillin and 50 mg/ml streptomycin. 
HepG2 is from ATCC. WDR24- and WDR59-knockout HepG2 cell lines were made from HepG2 
using the LentiCRISPR v2 system (Addgene, originated from Feng Zhang lab (46)) using the 
gRNA-encoding primers. hWDR24 F: CACCG TCA GGG TTG GCG CGC TCG AC, hWDR24 
R: AAAC GTC GAG CGC GCC AAC CCT GA C, hWDR59 F: CACCG ACC CGC GCA AAC 
GTC GGT AA, and hWDR59 R: AAAC TTA CCG ACG TTT GCG CGG GT C. After 
LentiCRISPR infection, multiple HepG2 cell clones with stable loss of targeted proteins were 
isolated through immunoblotting and used for the experiments. Primary hepatocytes were isolated 
from two-month-old control (Wdr24f/f) and liver-specific Wdr24-knockout (Alb-Cre/Wdr24f/f) 
mice as previously described (8). WT and AMPKɑ1/2 KO MEFs were gifts from the Ken Inoki 
lab. Palmitic acid treatment was done as previously described (8,47). HEK293A cells (Invitrogen) 
were transfected with plasmids expressing indicated proteins using the polyethylenimine (PEI, 
Sigma) method as previously described (48). Sestrin constructs of wild-type and mutant forms are 
described in our previous work (5). GATOR2 constructs were originated from the David Sabatini 
lab (19) and obtained through Addgene. AKT and Rictor constructs were made by PCR 
amplification of corresponding cDNA and subsequent subcloning into pLU-CMV/Flag or HA 
expression vectors. The Sin1 plasmid was a gift from the Do-Hyung Kim lab at the University of 
Minnesota. 
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Adenoviral and Lentiviral Production 
Adenoviruses and lentiviruses were produced at the University of Michigan Vector Core. 
For adenoviral production, full-length human Sestrin2 coding sequence, attached to an N-terminal 
Flag tag, was cloned into the pACCMV shuttle vector and incorporated into the Adenoviral 
backbone at the Vector Core, to generate Ad-SESN2. Ad-GFP was used as the control. For 
lentiviral production, pLU-CMV-SESN2 lentiviruses expressing wild-type and mutant Sestrin2 
were formerly described (5). Lentiviruses expressing shRNA-Sestrin2 were also formerly 




Cells were lysed in cell lysis buffer with 0.3% chaps, clarified by centrifugation, then 
incubated with Flag-bead (A2220, Sigma), HA-bead (A2095, Sigma), Mouse IgG sepharose bead 
conjugate (3420, Cell Signaling), or Rictor sepharose bead conjugate (5379, Cell Signaling) on a 
rotisserie at 4°C for 2 hours or overnight. The immunocomplexes were washed 6 times with the 
lysis buffer, samples were boiled with SDS sample buffer for 5 min at 95°C and analyzed by 
immunoblotting. 
 
In vitro PI3K assay 
The assay was performed as previously described (49). In brief, HepG2 cells were 
incubated with Ad-GFP or Ad-SESN2 for 48 hours and replaced with serum free DMEM. After 
12 hours, cells were treated with water (control) or 100nM insulin for 3 min, then harvested. 
Lysates were immunoprecipitated with p-Tyr antibodies (9411, Cell Signaling) conjugated to a 
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protein G/A bead, subjected to a lipid kinase assay with γ-32P-ATP and phosphotidylinositol, then 
subjected to thin layer chromatography and autoradiography to visualize PI3P. 
 
In vitro mTORC2 kinase assay 
HepG2 cells were treated with Ad-GFP or Ad-SESN2 and serum starved overnight. 
Lysates were immunoprecipitated with anti-Rictor antibodies conjugated to a protein G/A bead, 
subjected to a kinase assay with ATP and recombinant full-length inactive His-AKT substrate 
(Millipore 14-279), then analyzed by immunoblotting, as previously described (50). 
 
Protein Identification by LC-Tandem MS 
HepG2 cells were infected with Ad-GFP or Ad-SESN2 for 24 hours. Lysates were then 
immunoprecipitated with anti-Flag bead on a rotisserie at 4°C for 2 hours then washed 7 times in 
cell lysis buffer (20mM Tris pH 7.6, 150mM NaCl, 1mM EDTA, 1mM EGTA, 2.5mM sodium 
pyrophosphate, 1mM ß-glycerophosphate, 1mM Na3VO4, 0.3% Chaps), then 2 times in PBS. 
Samples were sent to the University of Michigan Proteomics Resource Facility and subjected to 
the protein identification service plus 3-hour LC-MS/MS analysis, according to their standardized 
procedure as described below. 
The beads were resuspended in 50 µl of 0.1M ammonium bicarbonate buffer (pH~8).  
Cysteines were reduced by adding 50 µl of 10 mM DTT and incubating at 45° C for 30 min.  
Samples were cooled to room temperature and alkylation of cysteines was achieved by incubating 
with 65 mM 2-Chloroacetamide, under darkness, for 30 min at room temperature.  An overnight 
digestion with 1 µg sequencing grade, modified trypsin was carried out at 37 °C with constant 
shaking in a Thermomixer.  Digestion was stopped by acidification, and peptides were desalted 
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using SepPak C18 cartridges, using the manufacturer’s protocol (Waters).  Samples were 
completely dried using vacufuge.  Resulting peptides were dissolved in 8 µl of 0.1% formic 
acid/2% acetonitrile solution, and 2 µls of the peptide solution were resolved on a nano-capillary 
reverse phase column (Acclaim PepMap C18, 2 micron, 50 cm, ThermoScientific), using a 0.1% 
formic acid/2% acetonitrile (Buffer A) and 0.1% formic acid/95% acetonitrile (Buffer B) gradient 
at 300 nl/min over a period of 180 min (2-22% buffer B in 110 min, 22-40% in 25 min, 40-90% 
in 5 min, followed by holding at 90% buffer B for 5 min and re-equilibration with Buffer A for 25 
min).  Eluent was directly introduced into Orbitrap Fusion tribrid mass spectrometer (Thermo 
Scientific, San Jose CA), using an EasySpray source.  MS1 scans were acquired at 120K resolution 
(AGC target=1x106; max IT=50 ms).  Data-dependent collision induced dissociation MS/MS 
spectra were acquired using Top speed method (3 seconds), following each MS1 scan (NCE ~32%; 
AGC target 1x105; max IT 45 ms).   
Proteins were identified by searching the MS/MS data against H. Sapiens database 
(UniProt; 2016-11-30 download, 42054 entries) using Proteome Discoverer (v2.1, Thermo 
Scientific).  Search parameters included MS1 mass tolerance of 10 ppm and fragment tolerance of 
0.2 Da; two missed cleavages were allowed; carbamidimethylation of cysteine was considered 
fixed modification and oxidation of methionine, deamidation of asparagine and glutamine were 
considered as potential modifications.  False discovery rate (FDR) was determined using 
Percolator and proteins/peptides with an FDR of ≤1% were retained for further analysis. 
 
Immunocytochemistry 
Ad-GFP or Ad-SESN2 treated HepG2 were grown on coverslips overnight. After 
incubation with serum free DMEM overnight, cells were fixed with 4% paraformaldehyde and 
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permeabilized with 0.2% Triton X-100. Cells were incubated with 3% BSA, and then with primary 
antibodies (1:1000) in PBS for 2 hrs. After washing, cells were incubated with Alexa fluor-
conjugated secondary antibodies (1:1000) for 1 hr, washed with PBS, counterstained with DAPI 
(Invitrogen), and mounted in Vectashield anti-fade mounting media (H-1000). Images were 
captured under a Leica SP5X confocal microscope. 
 
Cell Fractionation 
Cytosol and membrane protein fractions were isolated using the Mem-PER Plus Membrane 




Results are presented as mean ± SEM for line graphs and mean ± SD for bar graphs. 
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Concurrent Activation of Growth Factor and Nutrient Arms of mTORC1 
Induces Oxidative Liver Injury 
Abstract 
mTORC1 is a protein kinase important for metabolism and is regulated by growth factor 
and nutrient signaling pathways, mediated by the Rheb and Rag GTPases, respectively. Here we 
provide the first animal model in which both pathways were upregulated through concurrent 
mutations in their GTPase-activating proteins, Tsc1 and Depdc5. Unlike former models that 
induced limited mTORC1 upregulation, hepatic deletion of both Tsc1 and Depdc5 (DKO) 
produced strong, synergistic activation of the mTORC1 pathway and provoked pronounced and 
widespread hepatocyte damage, leading to externally visible liver failure phenotypes, such as 
jaundice and systemic growth defects. The transcriptome profile of DKO was different from single 
knockout mutants but similar to those of diseased human livers with severe hepatitis and mouse 
livers challenged with oxidative stress-inducing chemicals. In addition, DKO liver cells exhibited 
prominent molecular pathologies associated with excessive endoplasmic reticulum (ER) stress, 
oxidative stress, DNA damage and inflammation. Although DKO liver pathologies were 
ameliorated by mTORC1 inhibition, ER stress suppression unexpectedly aggravated them, 
suggesting that ER stress signaling is not the major conduit of how hyperactive mTORC1 produces
 
3 This chapter represents a published manuscript: Cho CS*, Kowalsky AH*, Namkoong S, Park SR, Wu S, Kim B, 
James A, Gu B, Semple IA, Tohamy MA, Solanki S, Cho US, Greenson JK, Shah YM, Kim M, Lee JH. Concurrent 
activation of growth factor and nutrient arms of mTORC1 induces oxidative liver injury. Cell Discovery (2019) 
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liver damage. Interestingly, superoxide scavengers N-acetylcysteine (NAC) and Tempol, 
chemicals that reduce oxidative stress, were able to recover liver phenotypes, indicating that 
mTORC1 hyperactivation induced liver damage mainly through oxidative stress pathways. Our 
study provides a new model of unregulated mTORC1 activation through concomitant upregulation 
of growth factor and nutrient signaling axes and shows that mTORC1 hyperactivation alone can 
provoke oxidative tissue injury. 
 
Introduction 
Mammalian target of rapamycin complex 1 (mTORC1) is a protein kinase complex that 
promotes cellular anabolism in response to insulin/growth factor stimuli and nutrient abundance 
(1-4). Regulation of mTORC1 is believed to be mediated by two small G proteins, Rheb and Rag 
(4,5). The tuberous sclerosis complex (TSC) and the GAP activities Towards Rags 1 complex 
(GATOR1) are GTPase-activating proteins (GAPs) that regulate Rheb and Rag, respectively (4,5). 
TSC, consisting of the TSC1, TSC2, and TBC1D7 proteins, mediates growth factor and energy 
signals to mTORC1 (6,7), while GATOR1, consisting of DEPDC5, NPRL2 and NPRL3 proteins 
are essential for amino acid sensing (8,9) and stress response (10) of the mTORC1 pathway. 
DEPDC5 is a component of GATOR1 that inhibits mTORC1 by binding and inhibiting 
Rag (8,9). DEPDC5 is also implicated in various human pathologies including brain and liver 
diseases (11-15). Genetic variations in the DEPDC5 locus were associated with hepatitis C virus 
(HCV)-induced hepatocellular carcinoma in a Japanese population (13), HCV-induced fibrosis 
progression in a European population (14), and hepatitis B virus (HBV)-related 
hepatocarcinogenesis in a Chinese population (15). However, whether DEPDC5 regulates liver 
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homeostasis and how it affects liver disease progression has not been investigated in an intact 
animal model. 
mTORC1, the DEPDC5 and TSC1 target, is an important metabolic regulator in the liver 
(2,3). mTORC1 activation is important for upregulating protein translation by phosphorylating 
two substrates: p70 ribosomal protein S6 kinase (S6K) and translation initiation factor 4E-binding 
protein 1 (4E-BP1) (1). mTORC1 also upregulates lipid and nucleic acid synthesis while 
downregulating autophagic catabolism through inhibition of unc-51-like autophagy activating 
kinase (ULK1) (1-4). Therefore, mTORC1 regulation is thought to be critical for maintaining 
metabolic homeostasis in the liver (2,3). Indeed, disrupting mTORC1 through liver-specific 
deletion of Raptor, an essential subunit, induced spontaneous liver damage associated with 
inflammation and fibrosis (16). This accelerated liver carcinogenesis upon administration of 
diethylnitrosamine (DEN), a chemical hepatocarcinogen (16). Activating mTORC1 through 
hepatocyte-specific deletion of Tsc1 (Tsc1Δhep) also produced liver inflammation and 
carcinogenesis in aged mice, but these pathologies were not obvious in young mice (17,18). 
Given the importance of DEPDC5 in nutrient and stress-dependent mTORC1 regulation 
(8-10), DEPDC5 could be an important regulator of mTORC1 in hepatocytes. To understand the 
genetic role of DEPDC5 in the liver, we generated Depdc5Δhep mice, which have hepatocyte-
specific deletion of the Depdc5 gene. Similar to Tsc1Δhep mice, Depdc5Δhep mice showed slight 
elevation in mTORC1 activity and exhibited mild inflammation and fibrosis in advanced age. 
However, when Depdc5Δhep mice were crossed to Tsc1Δhep mice, a much more striking phenotype 
was observed. Although individual deletions of Depdc5 or Tsc1 in the liver only slightly 
upregulated mTORC1 with no gross phenotypes, hepatocyte-specific Depdc5 and Tsc1 double 
knockout (DKO) mice had robust mTORC1 activation that induced prominent hepatocyte damage. 
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Consequently, serious liver failure associated with jaundice, hepatomegaly, fur discoloration and 
growth suppression were observed by 8 weeks of age. Transcriptomic analyses with RNA-seq and 
subsequent protein analyses indicated that DKO livers suffer excessive ER stress and oxidative 
stress leading to metabolic dysregulation, DNA damage and inflammation. Among these outputs, 
oxidative damage was the most critical in producing DKO pathologies, while ER stress signaling 
protected hepatocytes by suppressing mTORC1 in a negative feedback mechanism. 
 
Results 
Hepatic loss of Depdc5 induces hepatocellular hypertrophy in zone 3 
Immunoblot analyses of two-month-old mouse liver indicated that Alb-Cre/Depdc5F/F 
(Depdc5Δhep) mice lost hepatic Depdc5 expression and slightly upregulated the level of 
phosphorylated S6 (p-S6), a downstream marker of mTORC1 (Figure 3.1A). Hematoxylin and 
eosin (H&E) staining of liver sections revealed that two-month-old Depdc5Δhep mice had specific 
enlargement of pericentral zone 3 hepatocytes (Figure 3.1B and Supplementary Figure S3.1A), 
associated with locally elevated levels of p-S6 immunostaining (Figure 3.1C and Supplementary 
Figure S3.1A). 
Consistent with impaired zone 3 homeostasis, Depdc5Δhep mice were more extensively 
damaged from a high dose of acetaminophen (APAP), which provokes hepatocellular death most 
prominently in zone 3, compared to littermate controls (Supplementary Figure S3.1B). APAP-
induced hepatic mTORC1 activation (19-21) was also stronger in Depdc5Δhep mice 
(Supplementary Figure S3.1C). Therefore, Depdc5 appears to be critical for homeostatic 
regulation of zone 3 hepatocytes, suppressing hepatic mTORC1 activation and hepatocellular 




Figure 3.1: Liver-specific Depdc5 deletion induces slight upregulation of mTORC1 and 
inflammation. Two-month-old (A-C) or five-month-old (D-I) littermates of Depdc5Δhep and 
Depdc5F/F male mice were subjected to the following analyses. (A) Liver lysates were subjected 
to immunoblotting with indicated antibodies (left). Band intensities were quantified (n=3; right). 
(B, C) Liver sections were subjected to H&E staining (B) and anti-phospho-S6 immunostaining 
(c). Boxed areas are magnified in the insets. (D, E) Serum AST (D) and ALT (E) assays (n≥6). 
(F-I) Liver sections were subjected to H&E (F), F4/80 (G), TUNEL (H) and Sirius Red (SiRed, 
I) staining. TUNEL and SiRed-positive areas were quantified (n=3). Data are shown as mean ± 




Figure S3.1: Liver phenotypes of Depdc5Δhep mice. (A) Liver sections were subjected to H&E 
staining and anti- phospho-S6 immunostaining for 2-month-old females of the Fig. 3.1 cohort. 
Boxed areas are magnified in the insets. (B, C) After 12 hours of fasting, 2-month-old Depdc5F/F 
and Depdc5Δhep littermate mice of indicated gender were injected with 400 mg/Kg of APAP. After 
8 hours, livers were collected and analyzed by H&E staining (B) and immunoblotting (C). 
Damaged areas (n≥8) and band intensities (n=3) were quantified. (D, E) Liver lysates from 5-
month-old Depdc5F/F and Depdc5Δhep littermate male mice were subjected to immunoblotting 
(upper panels) and quantification (lower panels; n=4) to analyze mTORC1 signaling (D) and 
fibrogenic markers (E). (F,G) Two-month-old Depdc5F/F and Depdc5Δhep littermate male mice 
were kept on normal chow (LFD) (F) or high fat diet (HFD) (G) for three additional months. Livers 
from the 5-month-old mice were subjected to Oil Red O (ORO) staining. ORO-positive areas were 
quantified (right panels, n=3). Boxed areas are magnified in right panels. (H) Body weight was 
monitored during HFD feeding (male, n=8; female, n≥4). Data are presented as mean ± SEM. *P 
< 0.05; ***P < 0.001; ****P < 0.0001(Student’s t-test). When multiple parameters were assessed, 
the Holm-Šídák method was used to compare groups ($, P<0.05; $$, P<0.01; $$$$, P<0.0001). 
Scale bars, 200 μm.  
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Depdc5Δhep mice exhibit mild zone 3 inflammation as they age 
Five-month-old Depdc5Δhep mice demonstrated a slight but significant elevation in serum 
markers of liver damage: AST (Figure 3.1D) and ALT (Figure 3.1E). Although these values are 
still within normal clinical ranges, it is possible that there are subclinical levels of mild liver 
pathologies. Histological analyses indeed revealed occasional liver inflammation (Figure 3.1F, 
3.1G), hepatocyte death (Figure 3.1H) and fibrosis (Figure 3.1I) in five-month-old Depdc5Δhep 
mice. Immunoblot analyses also confirmed mTORC1 signaling upregulation (Supplementary 
Figure S3.1D) and increased fibrogenic marker expression in five-month-old Depdc5Δhep mice 
(Supplementary Figure S3.1E). Therefore, similar to previously described Tsc1Δhep mice (18), 
Depdc5Δhep mice also exhibited age-dependent development of spontaneous liver pathologies. 
Despite inflammatory phenotypes, Tsc1Δhep mice downregulated liver fat levels by 
blocking insulin-dependent lipogenic pathways (22). Likewise, Depdc5Δhep mice also exhibited 
reduced hepatic fat levels in both low fat diet (LFD, Supplementary Figure S3.1F) and high fat 
diet (HFD, Supplementary Figure S3.1G) conditions, without altering body weight gain 
(Supplementary Figure S3.1H). Therefore, the phenotypes exhibited by liver-specific Depdc5 
knockouts were generally similar to Tsc1 knockouts. 
 
Double deletion of Tsc1 and Depdc5 in liver suppresses systemic growth 
Rag and Rheb are the two most important small GTPases directly regulating mTORC1 
(4,5). Since Depdc5 and Tsc1 are critical for inhibiting Rag and Rheb, respectively, we 
hypothesized that mutations in these two genes may genetically interact (Figure 3.2A).  
To test the genetic interaction, we crossed Depdc5Δhep mice with Tsc1Δhep mice. Although 
the Depdc5Δhep/Tsc1Δhep double knockout (DKO) mice were born at the expected Mendelian ratios, 
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their growth was severely suppressed, and their fur was gray and patchy by two months old (Figure 
3.2B, 3.2C and Supplementary Figure S3.2A). These phenotypes were not observed in littermates 
of any other genotype, including Depdc5Δhep and Tsc1Δhep single knockouts. Although body and 
adipose tissue weights were drastically reduced in DKO mice, the liver weights were similar to 
controls and single knockout mice, resulting in a dramatic increase of liver/body weight ratio 
(Figure 3.2C and Supplementary Figure S3.2A). 
The body weight difference between control and DKO mice was not observed in 6 day-old 
mice (Supplementary Figure S3.2B), indicating that the DKO mice were not born with lower body 
weight and likely lose weight due to disease progression. 
 
DKO mice experience severe liver injury and failure 
Sera from the DKO mice were yellow, indicating bilirubin accumulation. All serum 
markers for liver damage and dysfunction were elevated prominently above normal clinical ranges 
(Figure 3.2D). Consistent with this, H&E staining revealed numerous necrotic lesions (arrows in 
Figure 3.2E and Supplementary Figure S3.2C) in DKO liver. The livers of DKO mice were 
extremely stiff, and Sirius Red staining revealed extensive pericellular fibrosis throughout the liver 
(Figure 3.2E, bottom). Fibrotic lesions were more intense around necrotic regions and often 
associated with proliferating bile ducts (Figure 3.2E, magnified images in blue and green boxes). 
All phenotypes were fully penetrant and prominently observed in both males (Figure 3.2) and 




Figure 3.2: Depdc5 and Tsc1 mutations synergistically provoke liver injury and damage.  
Control (Con), Tsc1Δhep (Tsc1), Depdc5Δhep (Depdc5) and Tsc1Δhep/Depdc5Δhep (DKO) male mice 
were generated as littermates and analyzed at two-months-old (n≥3). (A) Schematic of how the 
Rheb and Rag pathways regulate mTORC1. (B) Gross appearance of Con and DKO littermates. 
(C) Body weight, liver weight, epididymal white adipose tissue (eWAT) weight and liver/body 
weight ratios. (D) Serum liver panel assays. Blue shaded regions indicate clinically normal ranges. 
(E) Macroscopic view of liver (Macro), H&E staining and Sirius Red (SiRed) staining of liver 
sections. Arrows indicate necrotic lesions. Yellow boxed areas are magnified in the corresponding 
bottom row. Blue and green boxed areas are magnified in right panels. Sirius Red-positive fibrotic 
areas were quantified.  Data are shown as mean ± SEM. Effects of Tsc1 and Depdc5 mutations 
and their interaction (Tsc1×Depdc5) were assessed through two-way ANOVA (#, P<0.05; ##, 
P<0.01; ###, P<0.001; ####, P<0.0001), and statistical significance between Con and indicated 
groups were assessed through Tukey’s multiple comparison test ($$, P<0.01; $$$, P<0.001; $$$$, 






Figure S3.2: DKO mice exhibit mTORC1-dependent liver pathologies. (A) Body, liver, eWAT 
weights, and liver/body weight ratios were analyzed for females of the Fig. 3.2 cohort (n≥3 for 
Con and DKO; n=2 for single knockouts). (B) Body weights were analyzed for male pups at 6 
days after birth (n≥3). (C) H&E and SiRed staining images from livers of the Fig. 3.2 female 
cohort. (D, E) PCNA (D), BIP and PDI (E) immunostaining images from livers of the Fig. 3.2 
male cohort. Boxed areas are magnified in bottom panels (D). (F) BIP immunostaining images 
from livers of the Fig. 3.4 cohort. (G) Immunoblotting of ER stress markers (left panel) and 
quantification (right panel, n=3) for livers of the Fig. 3.4 cohort. β-actin image is the same as the 
one presented in Fig. 3.4f. (H) Immunoblotting of indicated proteins for livers of the Fig. 3.3 cohort. 
Data are presented as mean ± SEM. The Holm-Šídák method was used for multiple comparison 
tests ($, P<0.05; $$, P<0.01). Scale bars, 200 μm.  
 72 
 Further characterization of liver tissues with TUNEL staining revealed increased apoptotic 
cells in DKO liver (Figure 3.3a). In addition, both histology and immunoblot analyses confirmed 
that DKO livers had an increased expression of fibrogenic markers, significantly more than single 
knockouts (Figure 3.3B, 3.3C). Finally, we analyzed mTORC1 signaling by monitoring 
phosphorylation of its substrates, S6K and 4E-BP1. Although phosphorylation of these targets 
were upregulated in Depdc5Δhep and Tsc1Δhep, DKO mouse liver exhibited synergistic activation, 
at levels far beyond the level achieved by single knockout littermates (Figure 3.3D). This was not 
a simple, additive effect as the level of synergism was robust and statistically supported through 
two-way ANOVA (Figure 3.3D). Therefore, concomitant activation of the Rheb and Rag pathways 
produced a strong genetic interaction and synergistically increased fibrosis and upregulated 
mTORC1 (Figure 3.3). 
 
mTORC1 inhibition rescues DKO liver pathologies 
To test whether the pathological synergy of Tsc1 and Depdc5 mutations was due solely to 
mTORC1 hyperactivation, we injected DKO mice with rapamycin, a chemical inhibitor of 
mTORC1. Interestingly, during the course of rapamycin administration, DKO mice resumed 
normal growth (Figure 3.4A). After 10 days of rapamycin administration, liver/body weight ratios 
(Figure 3.4B), as well as all serum markers of liver damage and dysfunction (Figure 3.4C), showed 
dramatic recovery, indicating that mTORC1 hyperactivation is indeed the major cause of liver 
pathologies observed in DKO mice. Further confirming these observations, liver histology (Figure 
3.4D) and immunoblotting (Figure 3.4D-F) indicated that 10 days of rapamycin administration 
was sufficient to rescue all examined liver pathologies, including mTORC1 hyperactivation 




Figure 3.3: Depdc5/Tsc1 double knockout (DKO) livers upregulate fibrosis and mTORC1 
signaling. Mouse cohort described in Fig. 3.2 was subjected to histology (A, B) and 
immunoblotting (C, D) as outlined below. (A) TUNEL staining of liver sections. Boxed area is 
magnified in right panel. TUNEL-positive areas were quantified. (B) Liver sections were subjected 
to α-SMA staining. Boxed area was magnified in right panel. α-SMA staining intensities were 
quantified. (C) From the liver lysates, fibrogenic marker expression was analyzed through 
immunoblotting. Band intensities were quantified (n=3). (D) From the liver lysates, 
phosphorylation of mTORC1 substrates were analyzed through immunoblotting. Band intensities 
were quantified (n=3, mean ± SEM). Data are shown as mean ± SEM. ***P < 0.001 (Student’s t-
test). Effects of Tsc1 and Depdc5 mutations and their interaction (Tsc1×Depdc5) were assessed 
through two-way ANOVA (#, P<0.05; ##, P<0.01; ###, P<0.001; ####, P<0.0001), and statistical 
significance between Con and indicated groups were assessed through Tukey’s multiple 





Figure 3.4: mTORC1 inhibition rescues DKO liver pathologies. Littermate cohorts of six-
week-old DKO mice were injected daily with vehicle (Veh) or 10 mg/Kg rapamycin (Rap) for 10 
days (n≥4). For drug treatment experiments, mice were gender-matched with both males and 
females. (A) Body weight was monitored throughout the course of the experiment. (B) Liver/body 
weight ratio was measured at the experimental endpoint. (C) Serum markers for liver damage were 
analyzed. Blue shaded regions indicate clinically normal ranges. (D) Liver sections were analyzed 
by H&E, SiRed, and TUNEL staining. Boxed areas are magnified in lower panels. Fibrotic area 
and TUNEL area were quantified (n=3). (E, F) Liver lysates were subjected to immunoblotting 
(left panels) and quantification (right panels) to examine mTORC1 signaling (E) and fibrogenic 
markers (F).  Data are shown as mean ± SEM.  *P < 0.05; **P < 0.01; ***P < 0.001 (Student’s t-
test). Interaction between rapamycin and treatment days (Rap×Days) were assessed through RM 
two-way ANOVA (####, P<0.0001), and differences in individual data points were assessed 
through Sidak’s multiple comparison test ($, P<0.05; $$, P<0.01; $$$$, P<0.0001). For western 
blot quantification, the Holm-Šídák method was used to compare groups ($$, P<0.01; $$$, 
P<0.001; $$$$, P<0.0001). Scale bars, 200 µm. 
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 DKO liver pathologies are associated with elevated PCNA staining (Supplementary Figure 
S3.2D), which reflects regenerative responses to injury and damage. Rapamycin did not further 
elevate the PCNA staining intensity (Supplementary Figure S3.2D), indicating that it relieves 
DKO pathologies mainly by restoring hepatocellular homeostasis, but not by promoting liver 
regeneration. 
 
Relieving ER stress unexpectedly aggravated DKO liver pathologies 
Upregulated mTORC1 is known to increase ER stress (23). Consistent with this, DKO 
livers exhibited prominent ER stress marker activation (Figure 3.5A and Supplementary Figure 
S3.2E), significantly stronger than Tsc1 or Depdc5 single knockouts (Figure 3.5A). ER stress 
marker activation was strongly suppressed by rapamycin treatment (Supplementary Figure S3.2F, 
G), indicating that mTORC1 hyperactivation in DKO livers provokes ER stress. 
ER stress can be mitigated using chemical chaperones, such as tauroursodeoxycholic acid 
(TUDCA), which facilitates nascent protein folding in vivo (24,25). Therefore, we injected DKO 
mice with TUDCA to relieve ER stress. Unexpectedly, more than half of the mice died during the 
10 days of TUDCA administration (Figure 3.5B). This was surprising because previous work 
showed that TUDCA injection was beneficial for WT mice, not lethal (24,25). In addition, the 
surviving mice exhibited even greater liver/body weight ratios (Figure 3.5C) and more severe liver 
histopathology associated with increased area of necrotic and fibrotic lesions (Figure 3.5D). 
 In light of these observations, we questioned if TUDCA actually relieved ER stress in DKO 
mice. Immunoblotting showed that despite aggravated phenotypes, TUDCA generally reduced 




Figure 3.5: Relieving ER stress unexpectedly aggravated DKO liver pathologies. Mouse 
cohort described in Fig. 3.2 was subjected to immunoblotting (A). Six-week-old DKO mice were 
injected daily with vehicle (Veh) or 500 mg/Kg TUDCA for 10 days (B-E; n≥9). For drug 
treatment experiments, mice were gender-matched with both males and females. (A) ER stress 
signaling markers were examined from the indicated liver lysates through immunoblotting (left 
panels) and quantification (right panels). (B) Mouse survival was monitored throughout the course 
of the experiment. The P value was calculated through a log-rank test. (C) Liver/body weight ratio 
was measured at the experimental endpoint. (D) Liver sections were analyzed through H&E and 
SiRed staining. (E) Liver lysates were subjected to immunoblotting (left panels) and quantification 
(right panels) to examine ER stress signaling (top), mTORC1 signaling (middle) and fibrogenic 
markers (bottom). Data are presented as mean ± SEM (n≥3) or actual values (B). *P<0.05 
(Student’s t-test). Effects of Tsc1 and Depdc5 mutations and their interaction (Tsc1×Depdc5) were 
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assessed through two-way ANOVA (#, P<0.05; ##, P<0.01; ###, P<0.001; ####, P<0.0001), and 
statistical significance between Con and indicated groups were assessed through Tukey’s multiple 
comparison test ($$, P<0.01; $$$, P<0.001; $$$$, P<0.0001). For western blot quantification, the 
Holm-Šídák method was used to compare groups ($, P<0.05; $$, P<0.01; $$$$, P<0.0001). Scale 
bars, 200 µm. 
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were significantly downregulated after TUDCA treatment; however, some markers, PDI and 
CHOP, did not change. Interestingly, mTORC1 signaling markers were all upregulated after 
TUDCA treatment (Figure 3.5E, middle), suggesting that the presence of ER stress signaling 
limited mTORC1 activation. Expression of fibrogenic genes increased after TUDCA treatment 
(Figure 3.5E, bottom), consistent with the observation that TUDCA and ER stress reduction 
actually worsened liver pathologies. These results indicate that ER stress is not a major conduit of 
DKO liver injury but may function as a negative feedback to limit mTORC1 activation. 
 
The DKO transcriptomic profile is distinct from those of control and single knockouts 
Due to the unexpected results from ER stress suppression, we tried to approach 
pathogenetic mechanisms underlying DKO phenotypes more systematically. Therefore, we 
determined the transcriptomic profiles of livers from control, Tsc1Δhep, Depdc5Δhep, and DKO mice 
through RNA sequencing (Supplementary Table S1, available at: https://doi.org/10.1038/s41421-
019-0131-9). Although Tsc1Δhep and Depdc5Δhep mice showed modest transcriptomic changes from 
control mice, DKO mice showed stronger deviations from the control liver transcriptomic profile 
(Figure 3.6A). Heat map analysis of the correlations between individual datasets further 
demonstrated that DKO livers have a unique transcriptome profile that are most strongly correlated 
with each other, but not as strongly with controls or single knockouts (Supplementary Figure 
S3.3A). Principal component analysis of all experimental replicates also indicated that Con, 
Tsc1Δhep and Depdc5Δhep samples exhibited relatively similar transcriptomic profiles, while DKO 
samples displayed a highly distinct profile (Figure 3.6B). Likewise, although transcriptomic 
changes induced by single deletion of Tsc1 or Depdc5 correlated relatively well, DKO-induced 




Figure 3.6: Depdc5/Tsc1 double knockout (DKO) livers have distinct transcriptome profiles 
from single knockouts and specifically upregulate oxidative stress genes. Mouse cohort 
described in Fig. 3.2 was subjected to RNA-seq analyses. (A) Comparison of gene expression 
between averaged control profile and individual RNA-seq profiles from liver tissues of control 
(n=3), Tsc1Δhep (n=2), Depdc5Δhep (n=2) and DKO (n=3) mice. Each dot represents a single mRNA 
species in a dataset that is color-coded. For correlations between the datasets, see Supplementary 
Fig. S3.3a. (B) Principal component analysis (PCA) depicting the relationship between individual 
RNA-seq profiles. Each dot represents an entire RNA-seq profile from a single liver sample. 
Distinction is depicted spatially; similar profiles are clustered close together, while different 
profiles are located far from each other. (C) Transcript clusters were generated using a k-means 
algorithm (n = 7), using mRNA expression fold change values of Tsc1, Depdc5, and DKO samples 
over Con samples. (D-I, K) Bar graphs representing the distribution of all genes (white bars) and 
ER stress-inducible genes (D), cytokine/chemokine pathway genes (E), fibrosis-associated genes 
(F), genes upregulated in late-stage fibrosis during human HCV infection (G), genes upregulated 
in human NASH with lobular inflammation (H), genes upregulated in human NASH with fibrosis 
(I) or genes induced in mouse liver at 12 hours after diquat (DQ) treatment (K). Gene enrichments 
in clusters 1 and 2 were examined by Fisher’s exact test, and P values were indicated on the graphs. 
(J, L) Comparison of gene expression fold changes induced in DKO livers (X axis in both panels) 
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and HCV pathology progression (J) or DQ injection, Sod1 mutation and both (L). Correlations 
were assessed by computing a nonparametric Spearman correlation (r); P<0.0001 for all 
correlation observations. m, List of representative genes that are consistently upregulated by DQ 
+ Sod1 mutation and DKO mutation. Heat map diagrams represent mRNA expression fold change 




Figure S3.3: The DKO transcriptome profile is distinct from controls and single knockout 
mutants and is characterized by stress response. (A) Heat map diagram depicting the 
correlation between individual RNA-seq profiles. (B) Comparison of mRNA expression fold 
change over control liver samples between indicated liver samples. Individual dots represent single 
mRNA species. (C-J) Heat map diagrams representing mRNA expression fold change from 
averaged control values (expressed as log2 values). Each column represents a liver sample from a 
different Con (C1-3), Tsc1Δhep(T1-2), Depdc5Δhep(D1-2), or DKO (K1-3) mouse. (K) Gene cluster 
enrichment analysis of major urinary proteins (MUPs). (L) Gene cluster enrichment analysis of 
Cytochrome P450s. Correlations between RNA-seq datasets were assessed by computing a 
nonparametric Spearman correlation (r); P<0.0001 for all correlation observations. Statistical 
significance of gene enrichments in a specific cluster was examined by Fisher’s exact test.  
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Figure S3.3B). All of these results congruently indicate that DKO livers have transcriptomic 
profiles distinct from control or single knockout liver tissues. 
 
The DKO liver resembles diseased human livers with inflammation and fibrosis 
To understand the nature of DKO-specific transcriptome differences, we classified the 
genes into 7 different categories through k-means clustering, according to their expression changes 
in Tsc1Δhep, Depdc5Δhep, and DKO livers (Figure 3.6C and Supplementary Table S2, available at: 
https://doi.org/10.1038/s41421-019-0131-9). Among the 7 clusters, only a small number of genes 
were strongly and consistently upregulated, clusters 1 and 2, or downregulated, clusters 6 and 7, 
in DKO mice (Figure 3.6C). Consistent with our immunoblotting findings (Figure 3.5A), ER 
stress-responsive genes, such as Atf4 and Chop/Ddit3, were most upregulated in DKO mice 
(Supplementary Figure S3.3C). However, when we analyzed the whole known set of ER stress-
inducible genes (26), they were not overrepresented in clusters 1 and 2 (Figure 3.6D), indicating 
that ER stress activation is not the major transcriptomic feature characterizing the DKO phenotype. 
This supports our pharmacological experiment showing that ER stress was not the conduit of liver 
pathology in DKO mice (Figure 3.5). 
In contrast to this, genes belonging to cytokine and chemokine signaling pathways were 
highly enriched in clusters 1 and 2 (Figure 3.6E) and prominently upregulated in DKO livers 
(Supplementary Figure S3.3D), indicating that inflammatory pathways characterize the DKO 
transcriptome. In addition, genes upregulated during tissue fibrosis, such as collagens, matrix 
metalloproteinases (MMPs), tissue inhibitors of metalloproteinase (TIMPs) and TGF-beta 
pathway genes, were also highly enriched in clusters 1 and 2 (Figure 3.6F) and induced in DKO 
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livers (Supplementary Figure S3.3E). These are consistent with the extensive liver damage and 
fibrosis phenotypes we observed in the DKO mice. 
Based on these observations, we were curious if the gene expression changes in DKO 
mouse livers had any resemblance to those induced by inflammation and fibrosis in human liver 
diseases. For this, we utilized recently published transcriptome profile datasets that were 
constructed using fibrotic human liver tissues associated with HCV infection (27) or nonalcoholic 
steatohepatitis (NASH) (28). Genes upregulated in late-stage fibrosis during HCV infection 
(Figure 3.6G), lobular inflammation (Figure 3.6H) and fibrosis (Figure 3.6I) in NASH were highly 
enriched in clusters 1 and 2 (Figure 3.6G-I). Since cluster 1 and 2 genes are strongly upregulated 
in the DKO mouse liver (Figure 3.6C), these results indicate that DKO mouse liver models human 
inflammatory and fibrotic liver diseases associated with HCV and NASH. Furthermore, the gene 
expression changes associated with HCV fibrosis progression showed positive correlation with the 
changes induced by DKO (Figure 3.6J). These results collectively indicate that DKO mice 
experience severe liver inflammation and fibrosis, transcriptomically similar to those associated 
with human HCV and NASH pathologies. 
 
Oxidative damage response pathways were upregulated in the DKO transcriptome 
Inspection of clusters 1 and 2 identified that, in addition to the upregulated inflammation 
and fibrosis genes (Supplementary Figure S3.3D, E), oxidative stress (Supplementary Figure 
S3.3F) and DNA damage (Supplementary Figure S3.3G) response genes were strongly 
upregulated in DKO mice. Sestrins (Sesn1-3) and Redds (Ddit4 and Ddit4l), which are stress-
inducible negative feedback regulators of the mTORC1 pathway (10,29), were also upregulated in 
DKO livers (Supplementary Figure S3.3H). Induction of Sestrin2 was detected at the protein level 
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(Supplementary Figure S3.2H), and activation of AMPK, a downstream target of Sestrin2, was 
also observed in DKO livers (Supplementary Figure S3.2H). In contrast, major urinary proteins 
(Supplementary Figure S3.3I) and cytochrome P450s (Supplementary Figure S3.3J), whose 
expression is reduced during decreased growth hormone signaling (30) or upon inflammation and 
oxidative stress (31-33), respectively, were strongly downregulated in DKO mouse liver 
(Supplementary Figure S3.3K, S3.3L). Although many of the cytochrome P450 genes were 
downregulated, some genes, such as Cyp2b10 that is upregulated during hepatic damage and 
fibrosis (34,35), were upregulated (Supplementary Figure S3.3J) and found in cluster 1 
(Supplementary Figure S3.3L). These transcriptomic features indicate that DKO mouse livers 
specifically upregulate pathways responding to oxidative stress and subsequent DNA damage. 
 
DKO mouse liver exhibits excessive accumulation of superoxide radicals 
Upregulation of oxidative stress response genes implicates the presence of oxidative stress. 
Oxidative damage can precipitate a plethora of liver pathologies through DNA damage, 
inflammation, fibrosis, liver injury and hepatocyte death (36), which were all observed from the 
DKO mouse liver. Therefore, we measured the level of hepatic oxidative stress by dihydroethidium 
(DHE) staining which visualizes superoxide radicals (37). DKO livers had pronounced elevation 
of DHE staining intensity (Figure 3.7A), which was blunted by rapamycin treatment (Figure 3.7B). 
Interestingly, DHE intensity became more upregulated when DKO was treated with TUDCA 
(Figure 3.7C), consistent with upregulation of mTORC1 and aggravation of liver pathologies 
(Figure 3.5). These results indicate that DKO livers suffer severe oxidative stress with excessive 
accumulation of superoxide radicals. 
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Superoxide insults produce transcriptomic changes similar to those of DKO 
Superoxides can be formed by toxic chemicals such as diquat (DQ). Endogenous 
superoxide dismutase (Sod1) is important for reducing superoxides and suppressing their toxic 
effects (38). Genes whose hepatic expression is induced by DQ treatment (38) were highly 
enriched in clusters 1 and 2 (Figure 3.6K), suggesting that DKO livers upregulated DQ-induced 
genes. In addition, the gene expression changes induced by DQ treatment, Sod1 mutation, or both 
showed a positive correlation at the whole transcriptome level with DKO-induced changes (Figure 
3.6L). Accordingly, most of the DQ- and Sod1 mutation-induced genes were also upregulated in 
DKO livers, and these genes included those involved in oxidative stress response, DNA damage 
response and ER stress (Figure 3.6M and Supplementary Figure S3.3). Taken together, we 
hypothesized that oxidative stress, especially the accumulation of superoxides, was one of the most 
characteristic features of DKO mouse livers. 
 
Superoxide radicals mediate liver pathologies induced by hyperactive mTORC1 
To test whether the superoxide accumulation is the pathological conduit of DKO-induced 
mTORC1 hyperactivation, we treated the mice with Tempol, a membrane-permeable superoxide 
dismutase mimetic (39,40). As expected, Tempol was highly effective in reducing DHE staining 
in DKO liver (Figure 3.7D). Interestingly, Tempol-treated DKO mice exhibited significant weight 
gain after 5 days of treatment (Figure 3.7E), indicating that like rapamycin, Tempol was able to 
release the DKO mice from systemic growth suppression. Furthermore, 10 days of Tempol 
administration was sufficient to reduce liver/body weight ratio (Figure 3.7F), as well as serum 




Figure 3.7: Superoxide dismutase mimetic Tempol corrects DKO liver pathologies. Mouse 
cohorts described in Figure 3.2, 3.4 and 3.5 were analyzed. Littermate cohorts of six-week-old 
DKO mice were kept on vehicle drinking water (Veh) or 0.064% Tempol-containing water for 10 
days (n≥6). For drug treatment experiments, mice were gender-matched with both males and 
females. (A-D) Dihydroethidium (DHE) staining of liver sections and quantification. (E) Body 
weight was monitored throughout the course of the experiment. (F) Liver/body weight ratio was 
measured at the experimental endpoint. (G) Serum markers for liver damage were analyzed. Blue 
shaded regions indicate clinically normal ranges. (H) Liver sections were analyzed by H&E 
staining. Boxed area is magnified in right panel. (I) Liver sections were analyzed by SiRed staining. 
Fibrotic areas were quantified. (J) Liver lysates were subjected to immunoblotting (left panels) 
and quantification (right panels) to examine ER stress markers (top), mTORC1 signaling (middle), 
and fibrogenic markers (bottom).  Data are presented as mean ± SEM (n=3). *P < 0.05; **P < 
0.01; ***P < 0.001; ****P < 0.0001 (Student’s t-test). Interaction between Tempol and treatment 
days (Tempol×Days) were assessed through RM two-way ANOVA (####, P<0.0001), and 
differences in individual data points were assessed through Sidak’s multiple comparison test ($$$$, 
P<0.0001). For western blot quantification, the Holm-Šídák method was used to compare groups 
($, P<0.05; $$, P<0.01;). Scale bars, 200 µm. 
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 and fibrotic (Figure 3.7I) lesions exhibited by the DKO mouse liver (Figure 3.7H, 3.7I). These 
observations were supported through western blot analyses, where Tempol treatment strongly 
reduced fibrotic marker expression in DKO mice (Figure 3.7J). Interestingly, ER stress marker 
expression was also decreased by Tempol, indicating that superoxide accumulation also 
contributed to the mTORC1-induced ER stress (Figure 3.7J). However, phosphorylation of 
mTORC1 downstream targets was not suppressed by Tempol, confirming that Tempol specifically 
reduced superoxide accumulation without affecting mTORC1 signaling (Figure 3.7J). Consistent 
with the observation that mTORC1 is still hyperactivated, Tempol administration did not suppress 
hepatocyte hypertrophy (Figure 3.7H, arrows), while other pathological features were substantially 
suppressed (Figure 3.7E-J). 
Suppression of liver pathologies was again observed when DKO mice were treated with 
N-acetylcysteine (NAC), another antioxidant that scavenges superoxide radicals (Supplementary 
Figure S3.4). Collectively, these results indicate that production of reactive oxygen species, such 
as superoxide radicals, is the major pathological conduit of how hyperactive mTORC1 in DKO 
mice induces liver injury and precipitates pathologies. 
 
DKO mice have defective glucose metabolism and hepatic insulin resistance. 
DKO mice experienced hypoglycemia (Figure 3.8A and Supplementary Figure S3.5A), 
likely due to hepatic dysfunction and subsequent reduction in hepatic glucose output. Blood 
glucose levels of DKO mice were not reduced in response to insulin (Figure 3.8B and 
Supplementary Figure S3.5B, S3.5C), and DKO hepatocytes in intact livers did not activate AKT 




Figure S3.4: N-acetylcysteine (NAC) relieves DKO liver pathologies. Littermate cohorts of six-
week-old DKO mice were injected daily with vehicle (Veh) or NAC (250 mg/kg) for 10 days 
(n≥10). For drug treatment experiments, mice were gender-matched with both males and females. 
(A) Body weight was monitored throughout the course of the experiment. (B) Liver/body weight 
ratio was measured at the experimental endpoint. (C) Dihydroethidium (DHE) staining of liver 
sections and quantification. (D) Serum markers for liver damage were analyzed. Blue shaded 
regions indicate clinically normal ranges. (E) Liver sections were analyzed by H&E staining. (F) 
Liver sections were analyzed by SiRed staining. Fibrotic areas were quantified. (G) Liver lysates 
were subjected to immunoblotting (left panels) and quantification (right panels) to examine ER 
stress markers (top), mTORC1 signaling (middle), and fibrogenic markers (bottom). Data are 
presented as mean ± SEM. *P < 0.05; **P < 0.01; ****P < 0.0001(Student’s t-test). Interaction 
between NAC and treatment days (NAC×Days) were assessed through RM two-way ANOVA 
(####, P<0.0001), and differences in individual data points were assessed through Sidak’s multiple 
comparison test ($, P<0.05; $$, P<0.01; $$$, P<0.001). For western blot quantification, the Holm-




Figure 3.8: Depdc5/Tsc1 double knockout mice exhibit insulin resistance and hepatocellular 
carcinoma. (A-C) After 4-6 hours of fasting, Two-month-old Con and DKO littermates (n≥9) 
were subjected to (A) glucose and (B) insulin tolerance tests (GTT and ITT, respectively). Data 
are normalized according to baseline glucose levels (B, right). (C) Livers were collected from Con 
and DKO littermates, after 4 hrs of fasting, before (–) or 5 min after (+) an insulin injection, 
homogenized and analyzed through immunoblotting (left) and quantification (right; n=6). (D) 
Tumor number and incidence of the indicated five-month-old mice (n≥3). All mouse strains except 
DKO were free of liver tumor. (E) Macroscopic images (Macro) and histology images of H&E, 
SiRed, Reticulin, Ki-67 and PCNA staining were shown for five-month-old DKO mouse livers. 
Arrowheads indicate approximate boundaries of tumor nodules. Boxed areas are magnified in right 
panels. Data are presented as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, NS 
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(P=0.0712, 0.1799 and 0.6796 in B-left, B-right and C, respectively) from a Student’s t-test. Scale 
bars, 200 µm (histology) and 1 cm (whole liver). 
 
Figure S3.5: DKO mice have glucose metabolism defects and HCC development. (A-C) After 
4-6 hours of fasting, two-month-old Con and DKO female littermates (n≥7) were subjected to (a) 
glucose and (B) insulin tolerance tests (GTT and ITT, respectively). Data are normalized according 
to baseline glucose levels (C). (D-F) Additional histology images for Figure 3.8E upper right (D), 
8E middle left (E) and 8E middle right (F) are presented. Arrowheads indicate approximate 
boundaries of tumor nodules. Data are presented as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001, NS (P=0.1050) from a Student’s t-test. Scale bars, 200 μm.  
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mTORC1 and ER stress hyperactivation, both of which are known to provoke insulin resistance 
by blocking the insulin receptor-AKT pathway (24,41). 
 
DKO mice develop hepatocellular carcinoma. 
Although Depdc5Δhep or Tsc1Δhep mice developed mild inflammation at 5-6 months (Figure 
3.1) (18), they did not exhibit liver cancer until they reached 9-15 months (17,18). Since DKO 
mice experienced more pronounced liver damage at a much earlier age, we hypothesized that DKO 
livers would more quickly progress to liver cancer. Indeed, five-month-old mice revealed 
macroscopically visible liver tumors (Figure 3.8D, 3.8E, Macro). More tumor nodules were 
discovered in histological sections (Figure 3.8E, H&E, and Supplementary Figure S3.5D), which 
frequently displayed atypical mitotic features (Figure 3.8E, H&E right panel). The nodules were 
surrounded by fibrotic tissue, but the nodules themselves were devoid of fibrosis (Figure 3.8E, 
SiRed, and Supplementary Figure S3.5E). Most of these nodules also displayed markedly 
decreased reticulin staining (Figure 3.8E, Reticulin, and Supplementary Figure S3.5F) and 
elevated frequency of Ki-67 and PCNA staining (Figure 3.8E, Ki-67 and PCNA), indicating that 
they are indeed hepatocellular carcinoma. 
 
Discussion 
mTORC1 is a protein kinase important for liver metabolism and is regulated by two small 
GTPases, Rheb and Rag (1-4). Rheb mediates growth factor regulation, while Rag mediates stress 
and nutrient control. Although the Rheb and Rag pathways were extensively studied, there have 
been no genetic studies of whether these two pathways interact for physiological mTORC1 
regulation in an intact multicellular organism. 
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Rheb and Rag are regulated by their respective GAPs, TSC and GATOR1 (4,5). TSC1 and 
DEPDC5 are essential components of TSC and GATOR1, respectively. Tsc1 deletion in mouse 
liver produced pleiotropic metabolic phenotypes such as suppression of fat oxidation (42) and 
ketogenesis (43), increased FGF21 production (44), and decreased insulin sensitivity and 
lipogenesis (22). However, Tsc1 deletion in the liver (Tsc1Δhep) did not cause gross pathologies in 
young mice, although it promoted age-associated liver inflammation and carcinogenesis in one-
year-old mice (17,18). A physiological role for Depdc5 in the liver was not formerly investigated 
until the current study. Here, we showed that Depdc5 deletion in mouse liver upregulated hepatic 
mTORC1 most prominently in zone 3, where oxygen and nutrients are relatively scarce. Since 
GATOR1 is important for suppressing mTORC1 in nutrient-depleted conditions (8), it is plausible 
that GATOR1 is critical for regulating mTORC1 in zone 3 hepatocytes. After maturation and aging 
of Depdc5Δhep mice, mTORC1 upregulation became more pronounced and resulted in phenotypes 
similar to Tsc1Δhep mice, such as mild inflammation and decreased fat levels. Consistent with their 
similar mild phenotypes, Depdc5Δhep and Tsc1Δhep mice had similar transcriptomic profiles that 
were only moderately different from the wild-type profile. 
By crossing Depdc5Δhep mice with Tsc1Δhep mice, we showed that mutations in both Depdc5 
and Tsc1 generate a synergistic genetic interaction and produce a very strong hyperactivation of 
mTORC1. This is the first genetic evidence in animal models confirming that the Rheb and Rag 
pathways indeed interact for mTORC1 regulation in a physiological context. mTORC1 
hyperactivation in DKO mice resulted in liver dysfunction associated with prominent hepatocyte 
injury and fibrosis by two-months of age. This led to dramatic elevation of liver damage markers 
in the serum. Excessive bilirubin accumulation in serum led to an externally observable jaundice 
phenotype. In addition, since the liver is the primary source of insulin-like growth factors that are 
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essential for systemic growth, liver failure in DKO mice also suppressed growth. At the liver 
transcriptome level, specific stress response pathways, such as oxidative stress, inflammation, 
DNA damage and cell death pathways were strongly upregulated. All of these striking phenotypes 
were not manifested in either Tsc1Δhep or Depdc5Δhep single knockout strains or in any formerly 
described models of mTORC1 activation, such as Deptor knockout mice (45). Therefore, our 
current work provides a unique model of unregulated mTORC1 activation and shows that 
mTORC1 hyperactivation by itself can disrupt hepatocellular homeostasis, provoking liver injury 
and failure. 
mTORC1 is regulated through multiple negative feedback loops. mTORC1 
hyperactivation is known to inhibit Akt through S6K- or Grb10-mediated feedback inhibition of 
insulin signaling (41,46,47). Since Akt is an mTORC1 upregulator, Akt inhibition can limit 
mTORC1 activation. However, at the same time, inhibition of insulin-AKT signaling can also 
precipitate metabolic insulin resistance. Correspondingly, DKO mouse livers exhibited strong 
insulin resistance, and hepatocytes from DKO mice did not activate AKT in response to insulin. 
Although the DKO liver suffers strong insulin resistance, the blood glucose level was rather 
strongly decreased due to the deterioration of hepatocyte homeostasis and subsequent reduction in 
hepatic glucose output. 
In addition to the feedback loop involving insulin signaling, Sestrins can also provide a 
negative feedback mechanism for the mTORC1 pathway. In Drosophila, Sestrin is an important 
feedback inhibitor of the mTORC1 pathway through Tsc1/2 (48) and Depdc5 (49) pathways. In 
the current work, we found that Sestrins expression levels were substantially elevated after deletion 
of Tsc1, Depdc5 or both. AMPK, one of the downstream effectors of Sestrins inhibiting mTORC1 
(10), was subsequently activated in these tissues. Redd1 (Ddit4) and Redd2 (Ddit4l), which inhibit 
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mTORC1 through Tsc1/Tsc2 upregulation (29), were also upregulated in mTORC1-activated liver 
tissues. Therefore, it is possible that, in our mTORC1 activation models, Sestrins and Redds may 
have resulted in negative feedback inhibition to limit mTORC1 activities. 
It was quite striking that all of the liver pathologies in DKO mice were almost completely 
rescued by only 10 days of rapamycin treatment. Liver/body weight ratios were restored to normal 
levels, and liver damage markers in the serum also recovered close to clinically normal ranges. 
Although rapamycin was historically considered a growth attenuator, rapamycin-mediated 
normalization of liver homeostasis actually promoted systemic growth in this specific DKO model. 
Upon rapamycin treatment, necrotic and fibrotic lesions in DKO mice disappeared, and 
hepatocellular ER stress, oxidative stress and apoptosis were all relieved. Therefore, mTORC1 is 
indeed the major conduit of how the Rheb and Rag pathways pathogenetically interact to produce 
liver injury and failure. 
mTORC1 upregulation increases protein synthesis, which can put a burden on protein 
folding machinery and therefore induce accumulation of unfolded proteins in the ER, also known 
as ER stress (23). DKO mouse livers exhibited upregulation of ER stress signaling at the protein 
level, confirming that mTORC1 hyperactivation in DKO mice indeed precipitated unfolded 
protein accumulation and ER stress. However, the ER stress response pathway was not 
overrepresented in the DKO transcriptome, raising questions of whether the ER stress pathway is 
important for DKO pathologies. Indeed, TUDCA, a chemical chaperone that effectively 
suppressed hepatocellular ER stress in DKO mouse liver, was completely ineffective in rescuing 
DKO liver pathologies. Instead, TUDCA-treated DKO mice increased mTORC1 activation, 
further potentiating liver pathologies in DKO mice to the point of fatality. Even in the surviving 
mice, TUDCA administration increased expression of fibrogenic markers and more extensively 
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damaged hepatocytes. It is possible that ER stress signaling somehow limits mTORC1 activation, 
reducing its negative consequences on liver health. These data also indicate that ER stress signaling 
is not the major mechanism of how hyperactive mTORC1 disrupts hepatocellular homeostasis. 
In addition to inducing ER stress, mTORC1 hyperactivation can elevate oxidative stress 
by altering mitochondrial metabolism (50,51), inhibiting autophagic elimination of dysfunctional 
mitochondria (48,52), and suppressing the superoxide-scavenging action of Sod1 (53). Indeed, 
DKO livers experienced severe oxidative stress associated with excessive accumulation of 
superoxide radicals and exhibited a transcriptomic profile that is similar to DQ-induced oxidative 
stress and Sod1 loss. This high level of oxidative stress can damage cellular macromolecules 
including DNA. Consistent with this, the DKO transcriptome also exhibited upregulation of some 
DNA damage response genes. Administration of chemical antioxidants that scavenge superoxide 
radicals, such as Tempol and NAC, effectively reduced hepatic oxidative stress. Surprisingly, 10 
days of antioxidant administration was sufficient to normalize almost every liver pathology 
parameter observed in DKO mouse liver and even restored normal growth. Since mTORC1 
signaling itself was not suppressed by chemical antioxidants, these results indicate that hyperactive 
mTORC1 signaling provokes liver failure primarily through the induction of superoxide radicals 
that injure hepatocytes. 
At the tissue level, mTORC1 hyperactivation produced crosstalk with a number of 
additional pathways. For instance, NF-kB target genes such as Il6 (54) and Cd44 (55), TGF-beta 
signaling targets genes Acta2, Mmp2 and Timp2 (56) and Hippo-Yap target genes Ctgf (57) and 
Notch2 (58), were all upregulated in DKO mice. These signaling pathways were implicated in 
inflammation-dependent acceleration of carcinogenesis in previous studies (59). Consistent with 
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the finding and former studies, we found that the DKO mice spontaneously developed HCC at 5 
months, a relatively early age. 
Our observations also provide an explanation of how human genetic variations in the 
DEPDC5 gene can accelerate HBV/HCV-associated liver pathologies such as hepatic fibrosis (14) 
and carcinogenesis (13,15). HBV and HCV infections upregulate mTORC1 by activating PI3K-
AKT signaling and/or inhibiting TSC, both of which subsequently activate Rheb (60,61). Genetic 
variations suppressing DEPDC5 function would upregulate Rag signaling, and this would 
synergistically interact with the HBV/HCV infection that elevates Rheb signaling. Concomitant 
upregulation of both Rag and Rheb axes would lead to mTORC1 hyperactivation that can 
precipitate oxidative liver pathologies, as observed in the DKO mice described here. Furthermore, 
we found that our DKO liver transcriptome is closely related with human HCV and NASH 
transcriptomes. Therefore, our DKO mice provide a novel mouse model for investigating the role 
of human DEPDC5 variations in accelerating liver pathologies associated with HCV and NASH. 
However, the DKO model currently described here does not involve an actual viral infection or 
virus-associated activation of adaptive immunity. Therefore, additional studies should be 
conducted in the context of actual HBV and HCV infection to gain a more direct translation of our 
findings into the corresponding human liver pathologies. 
In conclusion, we show that the Rag and Rheb pathways are both required for maximum 
mTORC1 activation in tissues. Correspondingly, double knockout of the Tsc1 and Depdc5 genes 
provokes prominent upregulation of mTORC1, disrupts hepatocellular homeostasis, and 
subsequently precipitates oxidative injury and subsequent liver failure. Our work provides a 
valuable model for examining the consequences of mTORC1 hyperactivation, understanding 
human liver pathologies associated with HCV, NASH and DEPDC5 variation, and developing 
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therapeutic strategies for treating such pathologies with mTORC1 inhibitors or antioxidant 
compounds. 
 
Materials and Methods 
Mice and Diet 
Depdc5F/F (EM: 10459) mice, originated from the HEPD0734_3_G10 embryonic stem cell 
clone, were obtained from the European Mouse Mutant Archive. Depdc5F/F mice were bred to 
Albumin (Alb)-Cre to produce hepatocyte-specific knockout mice. DKO mice were generated by 
interbreeding Depdc5F/F and Tsc1F/F mice (17,62), then breeding progeny with Alb-Cre mice. 
Depdc5 single knockout experiments were done in C57BL/6 background. Tsc1 mice were 
originally produced in a 129S4/SvJae background (17,62) but were backcrossed to C57BL/6 for 
more than three generations for DKO experiments. To minimize genetic and environmental 
variations, littermate controls were used throughout the study, and mice were cohoused. For 
instance, Depdc5Δhep (Alb-Cre/Depdc5F/F) and Depdc5F/F littermates were used for Depdc5 single 
knockout experiments. Alb-Cre/Tsc1F/+/Depdc5F/+ and Tsc1F/F/Depdc5F/F breeders produced 
control (Alb-Cre negative mice and Alb-Cre/Tsc1F/+/Depdc5F/+ mice), Tsc1Δhep (Alb-
Cre/Tsc1F/F/Depdc5F/+), Depdc5Δhep (Alb-Cre/Tsc1F/+/Depdc5F/F), and Tsc1Δhep/Depdc5Δhep (DKO, 
Alb-Cre/Tsc1F/F/Depdc5F/F) littermates that were analyzed for genetic interaction assays. Alb-
Cre/Tsc1F/F/Depdc5F/F males and Tsc1F/F/Depdc5F/F females produced DKO littermate cohorts for 
drug intervention experiments. Mice were maintained in filter-topped cages with cob bedding and 
given free access to autoclaved regular chow/low fat diet (LFD, Lab Diet 5L0D), high fat diet 
(HFD, Bio-Serv S3282), and water, as previously described (63). When indicated, freshly made 
rapamycin (10 mg/Kg body weight), tauroursodeoxycholic acid (TUDCA, 500 mg/Kg body 
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weight), N-acetylcysteine (NAC, 250 mg/Kg body weight) or vehicle (5% Tween 80, 5% PEG400; 
or PBS) solutions were administered once daily through intraperitoneal (i.p.) injections for the last 
10 days. A superoxide dismutase mimetic 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (Tempol, 
0.064%) was administered to mice through drinking water. Acetaminophen (APAP, 400 mg/Kg 
body weight) was administered through a single i.p. injection after 12 hours of fasting. Glucose 
(1g/Kg glucose) and insulin (0.65 U/Kg insulin) tolerance tests (GTT/ITT) were done according 
to previously described procedures (25). For acute insulin response studies, mice were put under 
a surgical plane of isoflurane anesthesia. First, one part of the liver was collected as an untreated 
control. Then 0.8 U/Kg insulin, diluted in PBS, was injected intravenously through the vena cava. 
After 5 min, the other parts of the liver were collected as an insulin-treated sample. Information 
regarding mouse number, age, gender, diet duration, drug dose, route and frequency are indicated 
in the corresponding Figure and Figure legends. All animal procedures were ethically approved by 
the Institutional Animal Care & Use Committee and overseen by the Unit for Laboratory Animal 
Medicine at the University of Michigan. 
 
Antibodies and Reagents 
Antibodies for DEPDC5 were generated from Pocono Rabbit Farm & Laboratory using 
bacterially expressed recombinant proteins. We obtained COL1A1 (sc-293182), Pro-COL3A1 (sc-
166316), PECAM-1 (sc-376764), MMP-2 (sc-53630), MMP-3 (sc-21732), MMP-9 (sc-393859), 
LOX (sc-373995), MMP-13 (sc-515284), CTGF (sc-365970), S6K (sc-230), eIF2α (sc-11386), 
ATF4 (sc-200 and sc-22800), and TIMP-3 (sc-373839) antibodies from Santa Cruz Biotechnology, 
Actin (9E10) antibody from Developmental Studies Hybridoma Bank, phospho-Thr389-S6K 
(9234), pThr172-AMPK (2535), pThr37/46-4E-BP (2855), 4E-BP (9452), pSer51-eIF2α (3398), 
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pThr980-PERK (3179), PERK (5683), PDI (3501), BIP (3177), CHOP (2895), pSer473-AKT 
(4060), AKT (4691), pSer236/239-S6 (2211) and S6 (2317) from Cell Signaling Technology, α-
smooth muscle actin (α-SMA, ab5694) antibody from Abcam, and F4/80 (MF48000) antibody 
from Invitrogen. Acetaminophen, NAC and Tempol are from Sigma, TUDCA is from Cayman 
Chemical, and rapamycin is from LC labs. 
 
Histology 
Liver tissues were fixed in 10% buffered formalin, embedded in paraffin and subjected to 
hematoxylin and eosin (H&E) staining and immunohistochemical staining as previously described 
(63). In brief, paraffin-embedded liver sections were incubated with primary antibody (1:100), 
followed by incubation with biotin-conjugated secondary antibodies (Vector Lab, BA-9200 or BA-
9401; 1:200) and horseradish peroxidase (HRP)-conjugated streptavidin (BD Biosciences, 554066; 
1:300). The HRP activity was visualized with diaminobenzidine staining. Hematoxylin 
counterstaining was applied to visualize nuclei. For α-SMA and Ki-67 staining, Alexa Flour 488 
or 594-conjugated secondary antibodies (Invitrogen) were used to visualize primary antibody 
staining. Terminal deoxynucleotidyl transferase dUTP Nick-End Labeling (TUNEL) assays were 
performed using In Situ Cell Death Detection Kit-TMR-Red (Roche). Dihydroethidium (DHE) 
staining was performed using freshly frozen liver sections and DHE (Thermo Fisher Scientific, 
D11347) as formerly described (25). To visualize collagen fibers, liver sections were stained with 
saturated picric acid containing 0.1% Sirius Red (SiRed, Sigma). For Oil Red O staining, OCT-
embedded frozen liver sections were dried and stained with fresh 0.5% Oil Red O solution for 15 
min then rinsed with 60% isopropanol. Reticulin staining was performed using a kit from 
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Polyscience (25094), following the manufacturer’s recommendation. Histology samples were 
analyzed under an epifluorescence-equipped light microscope from Meiji. 
 
Immunoblotting 
Cells and tissues were lysed in radioimmunoprecipitation assay (RIPA) buffer (50mM 
Tris–HCl, pH 7.4; 150mM NaCl; 1% sodium deoxycholate; 1% NP-40; 1% Triton X-100; and 
complete protease inhibitor cocktail (Roche)). Lysates were clarified by centrifugation, and protein 
concentration was normalized using Bio-rad protein assay dye reagent. Protein lysates were boiled 
in SDS sample buffer for 5 min, separated by SDS-PAGE, transferred to PVDF membranes and 
subjected to immunoblotting procedures. 5% blocking grade non-fat milk (170-6404 from Bio-
Rad) in TBST was used for membrane blocking and antibody incubation. 1X western blocking 
reagent (11 921 673 001 from Roche) in TBST was used for phospho-specific primary antibody 
incubation. Primary antibodies from Santa Cruz Biotechnology and Developmental Studies 
Hybridoma Bank were used at 1:100, and all the other primary antibodies were used at 1:1000. 
HRP-conjugated secondary antibodies were purchased from Bio-Rad and used at 1:2000. 
Chemiluminescence was detected using LAS4000 (GE) systems.  
 
Serum Chemistry 
Blood was obtained by cardiac puncture and separated by centrifugation to obtain serum. 
Serum chemistry markers associated with liver cytotoxicity (ALT, alanine aminotransaminase; 
AST, aspartate aminotransferase) or liver function (ALP, alkaline phosphatase; TBIL, total 
bilirubin) were obtained through standard operating procedures using the Liasys clinical chemistry 
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system (AMS Alliance) within the In Vivo Animal Core of the Unit for Laboratory Animal 
Medicine. 
 
RNA-Seq Data Analysis 
10 µg of DNAase I-treated total RNA, purified from liver tissues of control 
(Tsc1F/F/Depdc5F/F; n=3), Tsc1Δhep (Alb-Cre/Tsc1F/F; n=2), Depdc5Δhep (Alb-Cre/Depdc5F/F; n=2) 
and DKO (Alb-Cre/Tsc1F/F/Depdc5F/F; n=3) mice, were submitted to BGI for mRNA enrichment, 
library construction and sequencing (BGISeq 50SE), and processed through standard experimental 
and analytical pipelines. Each sample produced more than 20M clean reads, that were mapped to 
the mm9 reference genome using STAR (64). Then, Cufflinks was used to generate Fragments Per 
Kilobase of transcript per Million mapped reads (FPKM) table (65), supplied as Supplementary 
Table S1. Genes with more than 0.5 FPKM values in every dataset were used to perform 
correlation and k-means clustering analyses. The accession number for the RNA-seq data reported 
in this paper is GSE136684. 
As formerly described (66), gene enrichment analyses were performed to identify whether 
a subset of genes were significantly overrepresented in specific gene clusters. Inflammation and 
fibrosis upregulated gene lists were obtained from recent transcriptome data on human liver 
samples with HCV-associated fibrosis (27) and nonalcoholic steatohepatitis (NASH) (28). From 
the HCV dataset, disease progression-associated fold changes of differentially expressed genes 
(the most stringent set with study-wide significance; both up- and down-regulated genes) were 
compared with the DKO-induced gene expression fold changes. The oxidative stress-upregulated 
gene list was obtained from livers of mice acutely treated with Diquat (DQ) for 12 hrs (38). From 
the same dataset, DQ-treated and Sod1-knockout induced fold changes of differentially expressed 
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genes (both up- and down-regulated genes; 1 hr DQ treatment) were compared with the DKO-
induced gene expression fold changes. The ER stress-upregulated gene list was obtained from 
tunicamycin-treated mouse embryonic fibroblasts (26). Cytokine and chemokine pathway gene 
lists were generated by selecting relevant genes from the list of genes whose names begin with 
Ccl/Ccr, Cxcl/Cxcr, Il/Ilr, Ifn/Ifnr and Tnf/Tnfr. The fibrosis-associated gene list was generated by 
selecting relevant genes from the list of genes whose names begin with Col, Mmp, Timp and Tgfb. 
Cytochrome P450 and major urinary protein gene lists were generated by selecting relevant genes 
from the list of genes whose names begin with Cyp and Mup, respectively. 
 
Quantification and Statistics 
Immunoblot images were quantified by densitometry, and protein expressions were 
expressed as relative band intensities. Histological images were analyzed by densitometric or 
fluorometric methods as appropriate. When indicated, data are shown as mean ± SEM. Statistical 
significance between two groups was calculated using a Student’s t-test (*, P<0.05; **, P<0.01; 
***, P<0.001; ****, P<0.0001). When multiple parameters were assessed, the Holm-Šídák 
method was used to compare groups ($, P<0.05; $$, P<0.01; $$$, P<0.001; $$$$, P<0.0001). A 
two-way ANOVA was used to evaluate the effect of Tsc1 and Depdc5 mutations and assess 
interactions and synergy between them (#, P<0.05; ##, P<0.01; ###, P<0.001; ####, P<0.0001), 
and statistical significance between two individual groups were assessed through Tukey’s multiple 
comparison test ($$, P<0.01; $$$, P<0.001; $$$$, P<0.0001). The effect of drugs on body weights 
was assessed through repeated measures (RM) 2-way ANOVA to evaluate the interaction between 
treatment and time (####, P<0.0001). Differences in individual data points were assessed through 
Sidak’s multiple comparison test ($, P<0.05; $$, P<0.01; $$$, P<0.001; $$$$, P<0.0001). Survival 
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curves were compared with a log-rank test. Statistical significance of gene enrichment in a specific 
cluster was calculated using Fisher’s Exact test. Correlations between RNA-seq datasets were 
assessed by computing nonparametric Spearman correlation (r); P<0.0001 for all correlation 
observations. GraphPad Prism 8 was used for all statistical analyses except k-means clustering 
analyses and gene enrichment analyses, which were performed using R.
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Conclusions and Future Directions 
Summary 
Sestrins are stress-induced proteins that protect against the pathological progression of 
many age and metabolic phenotypes. With two established anti-aging functions, reducing ROS 
and inhibiting mTORC1, Sestrins are well-positioned to protect cells from damage and disease 
progression. In this thesis, I have expanded our knowledge of Sestrin biology by defining a new 
mechanism of Sestrin2 regulation, where Sestrin2 activates AKT through GATOR2 and mTORC2. 
In addition to characterize other components in the Sestrin signaling network, I have generated a 
new mouse model with a hyperactive mTORC1 liver for use as a new model of both NASH and 
HCC liver diseases. However, further questions still remain regarding each of these topics. 
 
Sestrin2 and GATOR2 activate mTORC2 and AKT 
In Chapter 2, I first showed that Sestrin2 overexpression was sufficient to improve glucose 
and lipid regulation in HFD mice. We found improved responses to ITT, decreased lipid 
accumulation in the liver, and decreased gluconeogenic and lipogenic gene transcription (Figure 
2.1). Next, I wanted to understand mechanistically how this was occurring and saw huge AKT 
activation in the livers of the HFD mice with Sestrin2 overexpression, even without insulin 
stimulation (Figure 2.2A). This relationship between Sestrin2 expression and AKT activation also 




2.2C). Furthermore, I used a chemical inhibitor of mTORC1 and an AMPK-null cell line to 
establish that the mechanism of Sestrin2-induced AKT activation occurred independently of 
previously established Sestrin2 mechanisms (Figure 2.2E, 2.2F). To dissect this mechanism 
further, we performed kinase assays of established kinases upstream of AKT, PI3K and mTORC2. 
We found that Sestrin2 overexpression did not increase PI3K activity but did increase mTORC2 
activity (Figure 2.3D, 2.3E). 
 Next, we wanted to know whether GATOR2 was involved in the mechanism of Sestrin2-
induced AKT activation. Sestrin2 is known to bind GATOR2 through its D406 and D407 residue 
sites (1). Therefore, we tested if overexpressing Sestrin2 mutants that have lost their GATOR2 
binding function could still activate AKT and found that when Sestrin2 lost GATOR2, it also lost 
its ability to activate AKT (Figure 2.4A). I also confirmed this functional requirement for 
GATOR2 through knockdown and knockouts of WDR24, the GATOR2 subcomponent that binds 
to Sestrin2 (2). Furthermore, mice with liver-specific knockout of WDR24 were not able to benefit 
from Sestrin2 overexpression (Figure 2.4D-G). Determining that GATOR2 was involved in the 
mechanism of Sestrin2-induced AKT activation identified a novel function for GATOR2. 
 Through a series of immunoprecipitation assays, we found that GATOR2 bridged Sestrin2 
and mTORC2. Sestrin2 was already known to bind WDR24, and I found that the GATOR2 protein 
WDR59 was both critical and sufficient to bind Rictor, a key mTORC2 component (Figure 2.5B). 
The functional requirement of WDR59 for Sestrin2-induced AKT activation was also confirmed 
in a WDR59 KO cell line (Figure 2.5D). 
 Finally, I found that Sestrin2 regulates the subcellular localization of AKT by inducing its 
translocation to the plasma membrane. Not only did I find a physical association between Sestrin2 




domain of AKT (Figure 2.6C). The PH domain is important for AKT translocation to the plasma 
membrane (3), so I wanted to determine if Sestrin2 was in fact regulating AKT subcellular 
localization. It is possible that Sestrin2 binding to the PH domain is releasing AKT from its 
inhibitory conformation. Using both immunocytochemistry (Figure 2.6D) and fractionation 
experiments (Figure 2.6E-H), I was able to confirm that Sestrin2 overexpression enriches AKT on 
the membrane and requires GATOR2 to do so. 
 Overall, this work defined a novel signaling mechanism for Sestrin2 in regulating 
mTORC2 through GATOR2. Some questions still remain, however, about the details of this 
mechanism. First, I only identified the requirements of WDR24 and WDR59 for this mechanism, 
so future work could determine the requirement for the other three subcomponents of GATOR2: 
Seh1L, SEC13, and Mios. It is possible that only part of the GATOR2 complex is involved in the 
mechanism of Sestrin2-induced AKT activation, since other investigators have also found 
independent functions of GATOR2 subcomponents (4,5). Secondly, the exact mechanism of how 
Sestrin2 and GATOR2 induces membrane translocation and activation of AKT should be clarified. 
For example, one possibility is that Sestrin2, GATOR2, and mTORC2 are all shuttling AKT to the 
plasma membrane. However, it is also possible that Sestrin2, GATOR2, and mTORC2 are 
promoting Ser473 phosphorylation on AKT, and this subsequently promotes translocation to the 
plasma membrane. Finally, the next steps would be to evaluate Sestrin2 as a therapeutic candidate 
to improve glucose and lipid regulation in diabetic patients. Some challenges may be to determine 
mechanisms for effective delivery to the liver, developing Sestrin mimetics that can activate AKT 





Hyperactive mTORC1 liver mouse model 
 In Chapter 3, I generated and characterized two new mouse models. First, I generated 
Depdc5Δhep mice, which showed zone 3 hepatocyte enlargement, inflammation, and liver injury as 
they aged (Figure 3.1, S3.1). Then I generated a Tsc1Δhep/Depdc5Δhep DKO mouse, which showed 
systemic growth suppression and severe liver injury, even at a young age (Figure 3.2, S3.2, 3.3). 
Comparing DKO mice to littermate controls, I noticed three categories of significantly increased 
phenotypes: mTORC1 activity, ER stress, and liver injury. To which, I then tested three different 
interventions for each phenotype.  
First, we treated the DKO mice with rapamycin, an mTORC1 inhibitor. Strikingly, all 
pathological phenotypes were reversed with only 10 days of IP injections. This included resuming 
normal growth, reduced liver injury, inflammation, cell death, and fibrosis (Figure 3.4). Because 
our genetic modifications result in a hyperactive mTORC1 liver, this experiment confirmed that 
the pathological progression was, in fact, occurring through hyperactive mTORC1 signaling. 
The next intervention we tested was TUDCA, an ER stress reducer, that has been shown 
to be beneficial for WT mice (6,7). Surprisingly, TUDCA injections resulted in less than a 50% 
survival rate of the DKO cohort by 10 days (Figure 3.5B). Despite a reduction in most ER stress 
markers, all other liver injury phenotypes such as inflammation and fibrosis were significantly 
increased (Figure 3.5D, 3.5E). This data suggests that a potential negative feedback mechanism 
occurs through ER stress signaling that actually tempers the pathological progression of the 
hyperactive mTORC1 liver. 
To look at the DKO phenotype on a larger scale, we also performed transcriptomic analysis 
of WT, Depdc5Δhep, Tsc1Δhep, and DKO livers. We found that DKO transcriptomes had distinct 




upregulation of oxidative stress genes (Figure S3.3F) and transcriptomic profiles that resembled 
transcriptomes of patients with NASH (Figure 3.6H, 3.6I). Based on these findings, we then 
performed the third intervention, treating the DKO mice with Tempol, a reactive oxygen species 
reducer, to counter the oxidative stress. Tempol was also able to reverse the DKO pathologies: 
resuming normal growth, reducing liver injury, inflammation, and fibrosis (Figure 3.7). Taken 
together with the transcriptomic analysis, this suggests that the hyperactive mTORC1 liver injury 
was occurring through oxidative stress signaling. 
Finally, we also characterized the DKO mice under conditions of no interventions. We 
found that by 2 months of age, not only were the DKO mice exhibiting liver fibrosis (Figure 3.2E), 
but they were also insulin resistant (Figure 3.8A-C). These phenotypes may potentially make the 
DKO mouse a good model for NASH because of the quick fibrosis progression. Current models 
such as diet-induced NASH models, using methionine choline deficiency (MCD) or MCD-HFD, 
require 2 months of aging with an additional minimum 2 months of feeding (8), so our DKO model 
not only does not require a special diet but also no intervention and half of the time for NASH 
development. Furthermore, we found that 5-month-old DKO mice spontaneously generated 
hepatocellular carcinoma (HCC) with an incidence greater than 50% (Figure 3.8D). Current HCC 
mouse models require much longer time periods until tumorigenesis. For example, 
diethylnitrosimine (DEN) requires administration of the carcinogen in 15-day-old mice, then a 9-
month incubation period (8). Other chemical inducers such as carbon tetrachloride (CCl4) and 
thioacetamide (TAA) require repeat administration or combinatorial treatments with shortest times 
of HCC development of 5 months but this ranges to a year or longer (8). Diet-induced HCC models 
also exist, but HCC incidence is only 60-89% and may require 12 months of feeding (8). Finally, 




Therefore, our 5-month spontaneous HCC DKO mouse model may be a quick, low-maintenance 
HCC model for future studies. 
Overall, this work examined the genetic effect of deleting specific regulators upstream of 
mTORC1 in the liver. First, the Depdc5Δhep mice showed some mild inflammation and liver injury 
in 5-month-old mice. Then, Tsc1Δhep/Depdc5Δhep DKO mice showed huge pathological phenotypes 
by 2-months with transcriptomic profiles similar to NASH patients and exhibiting insulin 
resistance. By 5 months, the majority of the mice developed HCC without chemical administration. 
Mechanistically, we found that the liver injury seen in these DKO mice resulted from increased 
oxidative stress and could be recovered with daily injections of both rapamycin and Tempol for 
10 days. One major caveat to this mouse model is that the mice are quite sick, as witnessed by 
their significantly lower body weight. However, they are still reproductively viable, making them 
amenable to simple, littermate controlled breeding schemes for experimental setups. 
 
Perspectives 
From these two major experimental studies, this dissertation furthers our understanding of 
the Sestrin2 signaling network. First, I identified and defined a novel cell signaling pathway for 
Sestrin2 as a regulator of mTORC2. Sestrin2 is a concurrent mTORC1 inhibitor and mTORC2 
activator. These parallel mechanisms of regulation position Sestrin2 well for therapeutic 
evaluation because Sestrin2 is able to improve glucose and lipid regulation without the deleterious 
effects of mTORC1 activation. Sestrin2 mimetics or other chemicals that can strategically target 





Secondly, I generated a novel genetic mouse model with a hyperactive mTORC1 liver that 
replicates NASH and eventually HCC without subsequent intervention. This mouse model may be 
utilized for future investigation in liver disease because it is quick, thus cost-efficient, and low-
maintenance because it does not require chemical administration or a long latency period for 
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